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Abstract 
Respiratory chain impairment, interfering with energy production in the cell, is a major 
underlying cause of mitochondrial diseases. Yet, the surprising variety of clinical 
symptoms and the wide gap between ages of onset, as well as the involvement of 
mitochondrial impairment in ageing and age-related diseases continues to challenge our 
understanding of the pathogenic processes. The explanation for this complexity likely 
lays in the multiple roles of mitochondria in cellular function, a unique set of 
requirements for each cell types, and a convergence of a complex dual genetic 
predispositions and environmental factors. As the defined gene defect poorly predicts 
clinical manifestations in humans it remains essential to carefully assess the 
etiopathology of mitochondrial diseases. Given the heterogeneity of mitochondrial 
activity in cells and their functional relevance, clarifying the contribution of 
mitochondrial metabolic dysfunction at the cellular level is fundamental. For this 
purpose, we developed a novel enzyme histochemical method that enables precise 
quantification of COX deficiency in fresh-frozen tissues. I demonstrate that the loss of 
oxidative activity is detected at very low levels – an achievement unequaled by previous 
techniques and opens up new opportunities for the study of early disease processes or 
comparative investigations. Moreover, human biopsy samples of several genotypic 
origins were used and the successful detection of COX-deficient cells suggests a broad 
application for this new method. Lastly, the assay can be adapted to a wide range of 
tissues in the mouse and extends to other animal models, illustrated here with the fruit 
fly, Drosophila melanogaster. Overall, the new assay enables the quantification and precise 
mapping of single cells presenting impaired COX activity with the full extent of COX 
deficiency in tissues being made visible. This work makes the demonstration that the 
new enzyme histochemistry assay is a reliable tool for exposing COX-deficient cells and 
thereby expends new possibilities for future investigation. 
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Zusammenfassung 
Schädigungen der Atmungskette, welche die zelluläre Energiegewinnung 
beeinträchtigen, sind eine zentrale Ursache mitochondrialer Erkrankungen. Unser 
Verständnis der zugrundeliegenden pathogenen Prozesse wird jedoch durch die 
überraschende Vielfalt klinischer Symptome und das unterschiedliche 
Manifestationsalter mitochondrialer Erkrankungen sowie durch die Beeinträchtigung 
mitochondrialer Funktionen während des Alterungsprozesses und bei altersbedingten 
Erkrankungen fortwährend in Frage gestellt. Eine mögliche Erklärung für die 
Komplexität mitochondrialer Erkrankungen liegt möglicherweise in den vielfältigen 
Aufgaben der Mitochondrien und den einzigartigen metabolischen Anforderungen 
bestimmter Zelltypen begründet. Des Weiteren spielt vermutlich das Zusammenspiel 
von genetischen Faktoren zweier Genome, bestimmten Prädispositionen und 
Umweltfaktoren eine Rolle. Da genetische Defekte klinische Manifestationen im 
Menschen nur bedingt prognostizieren, ist es von zentraler Bedeutung, den 
Krankheitsverlauf mitochondrialer Erkrankungen sorgfältig einzuschätzen und zu 
beurteilen. Da die Aktivität der Mitochondrien und deren funktionelle Bedeutung 
abhängig vom Zelltyp sehr heterogen ist, ist es von fundamentalem Interesse, das 
Ausmaß einer mitochondrialen metabolischen Dysfunktion auf zellulärer Ebene 
aufzuklären. Aus diesem Grund haben wir eine neuartige enzymhistochemische 
Methode entwickelt, die eine präzise Quantifizierung der COX-Defizienz in 
frischeingefrorenen Geweben ermöglicht. Der Verlust der oxidativen Aktivität kann 
dabei bereits bei einem geringen Schweregrad nachgewiesen werden – die hier 
beschriebene Sensitivität der Methode übertrifft alle bisher beschriebenen Techniken 
und eröffnet neue Möglichkeiten, die frühen Stadien mitochondrialer Erkrankungen zu 
analysieren und vergleichende Untersuchungen zu machen. Darüber hinaus wurden 
humane Biopsien unterschiedlicher genotypischer Herkunft untersucht und die 
erfolgreiche Detektion COX-defizienter Zellen weist auf eine breite 
Anwendungsmöglichkeit dieser neuartigen Methode hin. Zusätzlich dazu kann diese 
Zusammenfassung 
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Methode für eine Reihe unterschiedlicher Gewebe angepasst werden und auch in 
anderen Tiermodellen, wie hier in der Fruchtfliege Drosophila melanogaster gezeigt, 
angewendet werden. Insgesamt gesehen ermöglicht diese neue Färbemethode die 
genaue Quantifizierung und die präzise Zuordnung einzelner COX-defizienter Zellen 
und macht somit das volle Ausmaß der COX-Defizienz im Gewebe sichtbar. Diese 
Arbeit demonstriert, dass die hier beschriebene neue enzymhistochemische 
Färbemethode eine verlässliche Technik darstellt, um COX-defiziente Zellen mit hoher 
Sensitivität zu identifizieren und bietet somit neue Anwendungsmöglichkeiten für 
zukünftige Analysen. 
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INTRODUCTION 
1.1 The origin of the mitochondrion 
The endosymbiosis event of an oxygen consuming bacteria inside a primitive 
eukaryote cell was a defining event in the history of life as we know it today (Sagan 
1967; Koonin 2010; O’Malley 2015). The small organelle known as the mitochondrion 
(plural: mitochondria) was once, billions of years ago, a free-living bacteria. The 
endosymbiosis idea took roots in the early observations of this organelle through the 
lens of a microscope as its resemblance to bacteria – rod-shaped structures with a double 
membrane –captured attention (Ernster & Schatz 1981). But it was through the discovery 
of small circular DNA inside the organelle that ultimately led the way to ascertain its 
bacterial ancestral origin (Nass & Nass 1963; Gray 2012).  
Through the development of DNA isolation methods and more advanced 
sequencing techniques, mitochondrial DNA (mtDNA) fragments from eukaryotes were 
aligned to sequences across all three domains of life (bacteria, archaea and eukaryota); 
mtDNA matches most closely the phylogenetic group of the α-proteobacteria genome, 
whereas the nuclear genome traces back to the archaea (Martin 2005; Gray 2012; Gray 
1999; Cedergren et al. 1988). Although the exact process by which eukaryotic cells have 
evolved and acquired the features observed today is still a matter of debate (Gray et al. 
2001; Gray 2017; Martin et al. 2015), it is fairly accepted that the endosymbiosis of 
proteobacteria has enabled the last eukaryotic common ancestor (LECA) to develop both 
in size and in complexity; an evolutionary breakthrough attributable to the increase in 
energy resources conveyed by the mitochondria (Lane & Martin 2010).  In mammals, it is 
estimated that more than 90% of cellular adenosine triphosphate (ATP) is produced by 
aerobic respiration in the mitochondria, a process known as the oxidative 
phosphorylation (OXPHOS) pathway. 
Chapter 1| Introduction 
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1.2 Mitochondrial structure 
Mitochondria are found in multiple copies within the cytoplasm of eukaryotic 
cells, enclosed by an outer and inner membrane. The outer membrane is porous to ions 
diffusion and small uncharged molecules easily enter through porin channels.  On the 
other hand, the inner membrane is impermeable and many times folded, forming 
mitochondrial cristae, and isolating the matrix; the inner most compartment of the 
mitochondria (Figure 1.1). The distinct areas provide the structural support for the 
coordination and regulation of several enzymatic reactions that define mitochondrial 
function (Green & Beinert 1955). Protein translocases on both membranes ensure the 
distribution of proteins assembled in the cytosol to be sorted within the right 
compartments of the mitochondria. 
Contrary to the porous nature of the outer membrane, the inner membrane 
selectively transports ions and protons across, thereby maintaining an electrochemical 
membrane potential of ~ 180 mV. This membrane potential is the result of coordinated 
efforts from specialized ion channels as well as from the movement of electrons and 
protons through the electron transport chain (ETC): a group of 4 complexes composed of 
reducing and oxidizing enzymes and electron carrying proteins such as heme- and 
flavo- proteins (reviewed in O’Rourke 2007). This highly controlled flux of ions is 
fundamental for mitochondrial response to energy demands and for ATP generation 
through the use of the proton-motive force by the ATP synthase. In the mitochondrial 
inner most compartment (the matrix), important enzymatic reactions take place, such as 
the tricarboxylic acid (TCA) cycle, fatty acid β-oxidation, steroids synthesis and the urea 
cycle.  Furthermore, the matrix is home to the mitochondrial genome - packed in small 
nucleoli - and is the site of mtDNA transcription, replication and translation.  
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Figure 1.1 | The mitochondrion and its structure. (A) Electron cryotomography showing 
mitochondria in heart tissue of young (20 weeks) mice. (B) 3D reconstruction of typical 
heart mitochondria in mice. Outer membrane is shown in yellow and the inner 
membrane and cristae in blue. Scale bars, 250 nm. Image adapted from Brandt et al. 2017, 
eLife (Open Access). 
 
1.3 Mitochondrial genome 
The mitochondrial genome universally encodes for proteins necessary for 
mitochondrial function. Proteins encoded within the animal mtDNA consist of subunits 
of the electron transport chain (Complex I, II, III and IV) as well as Complex V (ATP 
synthase). The translational components are also partly found in the mtDNA, namely 
ribosomal RNAs (rRNAs, 12S and 16S subunits), sometimes also the 5S rRNA, as well as 
complete or partial set of transfer RNAs (tRNAs) (Gustafsson et al. 2016; Gray 2012). 
Despite similarities across species, sequence analysis of full mitochondrial genome from 
diverse organisms has revealed that there exist a notable variability in size, gene content 
and arrangement across eukaryotes (reviewed in Gray et al. 1999). Mitochondrial 
genome size can be as small as 6 kilobase pairs (kbp) in the human malaria parasite 
(Plasmodium falciparum) or up to more than 200 kbp in a plant (Arabidopsis thaliana). In 
humans, as well as other mammals such as the common laboratory mouse Mus 
musculus, the circular double stranded mtDNA is ~ 16-17 kbp and encodes 37 genes 
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which consist of 13 proteins (polypeptides), 2 rRNAs (small and large subunit) and 22 
tRNAs (Figure 1.2). Under the control of the nucleus are more than 1000 additional 
proteins which make up the mitochondrial proteome (Calvo et al. 2016) - among them 
are proteins of the respiratory chains, regulatory proteins involved in mtDNA 
transcription and maintenance and part of the translation machinery such as ribosomal 
proteins (reviewed in Gustafsson et al. 2016). It is unclear why primarily genes encoding 
for the OXPHOS system have been retained in the organellar genome along with rRNAs 
and tRNAs. It is speculated that a local control of gene expression could be linked to 
changes in membrane potential and/or redox state and act as regulatory mechanism for 
metabolic needs (Allen 2015). The reasons for mitochondrial genome differences across 
species and the evolutionary driving force which led to gene loss or gene transfer to the 
nucleus remain unclear.  
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Figure 1.2 | Illustration of the dual genome regulation of mitochondrial protein synthesis 
and the mouse mtDNA organization. Most mitochondrial proteins are encoded in the 
nucleus and are synthesized in the cytoplasm, subsequently imported inside the 
mitochondria (mitochondrial outer membrane (OM), inner membrane (IM) and 
intermembrane space (IMS)). A Schematic representation of the double-stranded mtDNA 
molecule showing the heavy strand (HS) and light strand (LS), the origin of replication 
(OriH, OriL), two promoters (HSP, HSL) and the non-coding region (NCR). Genes are 
represented by colored rectangles including 22 tRNA genes (black rectangle, each tRNA 
is identified with a corresponding capital letter),  2 rRNAs (12S, 16S) and 13 mRNAs 
(CYTB, cytochrome b; CO1-3, cytochrome c oxidase subunit I-III; ND1-4, 4L, 5-6, NADH 
dehydrogenase subunit 1-4, 4L, 5-6; ATP6 and 8, ATP synthase F0 subunit 6 and 8). 
Illustration used with permission from Isokallio, M., 2017. The source and fate of 
mitochondrial DNA mutations using high-sensitivity next-generation sequencing 
technologies. (PhD Dissertation), Retrieved from Universitäts- und Stadtbibliothek Köln. 
 
Genes encoding for proteins necessary for mitochondrial function are therefore 
found on either the mitochondrial or the nuclear genome and spread across several 
chromosomes, including the X chromosome.  A particularity of the mitochondrial 
genome is that, unlike the nuclear DNA who is confined in the nucleus with two copies 
of each gene compacted into chromosomes, multiple copies of mtDNA reside within a 
mitochondrion (2-10 mtDNA molecules, depending on the type of cell or tissue) and 
several hundreds of mitochondria are found within each mammalian cell (Bogenhagen 
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& Clayton 1974). This impressive amount of mtDNA within a given cell enables 
mutations and sequence variations to be tolerated given that a certain threshold for 
energy production is not reached. Phenotypic expression of mitochondrial disease 
caused by mtDNA defect depends on the proportion of mutated mtDNA to the amount 
of wild-type mtDNA within a cell and segregation of mutant mtDNA across tissues 
partially explains the variation in clinical features typically observed in mitochondrial 
diseases (Turnbull & Rustin 2016). The term homoplasmy refers to cells or tissues where 
nearly all mtDNA molecules are identical, whereas heteroplasmy describes a situation 
where more than one mtDNA variant, which usually contains a deletion or a point 
mutation, is found within one organism (Larsson & Clayton 1995). Homoplasmic 
mtDNA deletions or point mutations that drastically impair the electron transport chain 
or the ATP synthase are embryonic lethal but at a low heteroplasmy level the mutated 
mtDNA molecules remain in the pedigree of families with asymptomatic individuals 
until a critical threshold is reached.  Because of the biological mechanisms defining 
mtDNA inheritance, heteroplasmy levels can change drastically between generations. In 
addition, every offspring of a mother carrying low levels of a heteroplasmic mutation 
will inherit the mutant mtDNA with an unpredictable variation in heteroplasmy levels 
between siblings (Taylor & Turnbull 2005). 
Inheritance of mitochondrial genome is normally strictly maternal; mitochondria 
from sperm are greatly outnumbered by the oocyte mitochondrial content and quickly 
eliminated after fecundation (Sato & Sato 2013). The term mitochondrial genetic 
bottleneck was given to the process by which segregation of mutated mtDNA randomly 
occurs during oogenesis giving rise to offspring with different load of mutant mtDNA 
(Laipis et al. 1988; Brown et al. 2001; Upholt & Dawid 1977; Olivo et al. 1983). Germline 
cells develop into mature oocytes that contain an impressive amount of mitochondria 
per cell – on average approximately 100,000 mitochondria are found in human oocytes 
(Chen et al. 1995) – but it was shown that primordial germ cells first divide into primary 
oocytes without mitochondrial biogenesis, thereby reducing the total amount of 
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mitochondria per cell and randomly distributing mutant and wild-type mtDNA 
molecules between immature oocytes (Wai et al. 2008, Figure 1.3).  
The complexity of mitochondrial genetic and the dual genetic control of 
mitochondrial functions are important fields of research which aim to better predict 
clinical outcome, to estimate the risk of maternal transmission of pathologic mtDNA 
mutation, and developing efficient treatment strategies. 
  
 
Figure 1.3 | Oocyte development and the bottleneck effect. Primordial germ cells divide in smaller 
primary oocytes where only a fraction of the mitochondria are randomly distributed, creating what 
is known as the bottleneck effect. This causes an unpredictable segregation of mutant mtDNA per 
oocyte and explains the variation in mutational load between generations and among offspring of a 
mother carrying low levels of pathogenic mtDNA mutations. Illustration adapted by permission 
from RightsLink Permissions Springer Customer Service Center GmbH: Springer Nature, Nature 
Reviews Genetics, (Mitochondrial DNA mutations in human disease, Taylor and Turnbull), 
COPYRIGHT, 2005. 
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1.4 Mitochondrial function 
Mitochondria are an integral part of eukaryote cells and as such are essential 
participants in several of the cell basic functions. Predominantly, mitochondria are 
specialized energy producing organelles (in the form of ATP molecules) but their role 
expands beyond that of ATP production to a more intricate coordination of basic cellular 
function. Mitochondria are involved in cell cycle events, cell signalling pathways, 
modulation of cellular response, regulation of metabolism and cell death through 
apoptosis (reviewed in Kasahara & Scorrano 2014; McBride et al. 2006).  
1.4.1 Oxidative phosphorylation 
Energy production in the form of ATP molecules is tightly regulated within the 
inner membrane of the mitochondria. The OXPHOS pathway is composed of enzymes 
within the inner membrane which effectively move protons (hydrogen atoms, H+) across 
and transfer electrons in a series of redox reaction ending with the reduction of oxygen 
to water molecules. The accumulation of protons in the intermembrane space creates a 
pH gradient and an electrical potential which drives the ATP synthase activity (Complex 
V). The mitochondrial respiratory chain produces the majority of ATP molecule; only a 
small fraction comes from anaerobic glycolysis in the cell cytoplasm. The electron 
transport chain takes place in four distinct complexes: Complex I, nicotinamide adenine 
dinucleotide (NADH) dehydrogenase; Complex II, succinate dehydrogenase, SDH; 
Complex III, cytochrome bc1 complex and Complex IV, cytochrome c oxidase, COX 
(Figure 1.4). Being at the center of mitochondrial metabolic activity, the discovery of 
those enzymes in the 1950s and subsequent investigation regarding their biological 
function is relevant to this work. Understanding the complex redox activity associated 
with enzymes within the electron transport chain has enabled histochemistry assays to 
be developed allowing researchers to specifically assess focal mitochondrial enzyme 
dysfunction in diseased tissue. Since respiratory chain complexes are assembled in the 
mitochondria from proteins encoded in both the nuclear genes and the mtDNA itself, 
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with the exception of Complex II which genes are found exclusively in the nuclear DNA, 
dysfunctional enzymatic activity in the mitochondria can be detected regardless if the 
problem is of nuclear or mitochondrial DNA in origin. 
 
Figure 1.4 | Electron transport chain. A simplified view of the electron transport chain 
within the inner membrane bilayer, showing the 4 enzyme complexes with the flow of 
electrons and protons. Complex I, II, III and IV are marked with roman numbers 
respectively. CoQ, coenzyme Q; Cytc, cytochrome c; e-, electron; H+, proton; IMS, 
intermembrane space; IM, inner membrane; M, matrix. 
 
The major source of electron entry into the respiratory chain is through removal of 
hydrogen from NADH by Complex I, resulting in proton translocation across the inner 
membrane and electron transfer to the membrane-bound ubiquinone molecule. Another 
source of electrons is through the enzymatic activity of Complex II: succinate which is 
generated within the citric cycle is stripped of two hydrogen atoms to form fumarate 
with the resulting reduction of flavin adenine dinucleotide (FAD) into FADH2 and 
subsequently the reduction of ubiquinone. Reduced ubiquinone move electrons to 
Complex III where cytochrome c serves as the next electron acceptor in the chain. 
Complex IV terminates the electron transfer with the oxidation of cytochrome c, proton 
translocation and reduction of oxygen to water molecules. Finally, the electrochemical 
gradient generated is used by the ATP synthase (Complex V) to generate ATP from 
adenosine diphosphate (ADP) and inorganic phosphate (Pi). Protons pass through a 
channel formed by 2 main subunits: F0, a hydrophobic octameric protein complex and F1, 
a hydrophilic subunit rotating upon the passage of protons (the proton-motive force) 
Chapter 1| Introduction 
10 
 
thereby catalyzing the production of ATP (Reviewed in Junge & Nelson 2015; Yoshida et 
al. 2001, Figure 1.5).  
 
Figure 1.5 | Illustration of the mammalian ATP synthase. The ATP synthase is composed 
of several subunits together forming a hydrophobic (F0) part, embedded in the 
mitochondrial inner membrane, and a hydrophilic (F1) multisubunit complex. On the 
passage of protons through the barrel-shaped F0 subunit (dashed arrows), a mechanical 
rotation of the F0 subunit (shown with a black arrow) provides the energy for ATP 
synthesis within the F1 subunit. Image adapted from Antoniel et al 2014, International 
Journal of Molecular Sciences (Open Access).  
 
1.4.2 Metabolic pathways within the mitochondria 
The OXPHOS system described above is central to mitochondrial function but is 
not the only metabolic activity attributed to this organelle. Indeed, mitochondria are also 
the site of other key metabolic events such as production of reducing equivalents by the 
TCA cycle, steroid synthesis – in mitochondria of specific cells of the adrenal glands, the 
gonads and the kidney (Miller 2013) – gluconeogenesis  and ketone bodies in the liver, 
as well as the urea cycle and amino acid synthesis. In addition, fatty acid β-oxidation 
which ultimately feeds into the OXPHOS system and contributes to a high yield of ATP 
production takes place within the mitochondrial matrix. The importance of fatty acid-
oxidizing metabolism is exemplified by human diseases associated with defect in either 
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transport of fatty acid into the mitochondria or defects in β-oxidation (Vishwanath 
2016). Fatty acids are taken up into the mitochondria and metabolized through repetitive 
4 step enzymatic reactions (dehydrogenation, hydratation, a second dehydrogenation 
step and finally thiolytic cleavage), the process ends when the chain of carbon atoms has 
been fully cleaved into several molecules of acetyl-CoA. In the mitochondria of the liver, 
acetyl-CoA does not enter the TCA cycle but is used for the synthesis of ketone bodies; 
another important source of alternative energy for many organs, particularly for the 
brain (Rinaldo et al.  2002).  
1.4.3 Control of mitochondrial activity 
Overall, metabolic events taking place in the mitochondria are unequivocally 
interlaced with that of the cell and have an incredible adaptability and responsivity to 
cellular demands. Given its structure, this feature seems coherent; mitochondria are 
built with an isolating double membrane equipped with several ion channels (as well as 
numerous exchangers and pumps), it contains specialized enzymes and a small genome, 
including its own transcription machinery. The details of the molecular pathways and 
biochemical events by which cellular metabolic demands are translated into a 
mitochondrial response are still largely unknown. 
Nevertheless, advancing research on the topic shows that mitochondrial activity 
is controlled through the convergence of distinct regulatory mechanisms that include: 
substrate limitation for ATP production (ADP and phosphate concentration), 
mitochondrial calcium concentration, tissue specific or developmental expression of 
isozymes, allosteric control (expression of small proteins affecting OXPHOS enzyme 
kinetics) and cell signalling induced phosphorylation and dephosphorylation of 
OXPHOS components. In addition, mitochondria form a network that dynamically 
reshapes itself upon fusion or fission events. Described as an integrated reticulum this 
reshaping of the mitochondrial architecture is thought to serve as a way for 
mitochondrial quality control as well as being part of the complex orchestration of 
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mitochondrial metabolism modulation (Shutt & McBride 2013; Scalettar et al. 1991). The 
equilibrium between the fused or fragmented state has been shown to correspond to 
cellular energetic state. For example, mitochondria will fragment when apoptosis signals 
are triggered (Liu et al. 1996) or will fuse and elongate during starvation (Gomes et al. 
2011). Furthermore, properly coordinated mitochondrial dynamic has been associated 
with successful progress of cellular events such as cell division (Kianian & Kianian 
2014), immune responses (Rambold & Pearce 2017) and tissue differentiation and 
development (Chen et al. 2003). The machinery behind fusion and fission include 
guanosine-5’-triphosphate (GTP)-dependent proteins, the mitofusin 1 and 2 (Mfn1 and 
Mfn2 located on the outer membrane) and optic atrophy 1 (OPA-1, located in the inner 
membrane) and the GTPase dynamin-related protein 1 (Drp1) which forms ring-like 
structure around the mitochondrial outer membrane and cause fragmentation (reviewed 
in Liesa et al. 2009). Several more genes involved in mitochondrial dynamic or its 
regulation have been identified or remain to be found but the last decade of research in 
the field has certainly exposed the crucial role of mitochondrial dynamic in cellular 
functions and health. Most of the pioneer work has been done on yeast or cell culture 
which begs the question as to how mitochondrial dynamic shapes tissue function in 
human or mouse tissues and what is the relevance of this in terms of the 
physiopathology of mitochondrial diseases. In physiological conditions, fusion and 
fission events take place to maintain a stable mitochondrial network that is adaptive to 
cellular demands. Human mitochondrial diseases such as axonal Charcot-Marie-Tooth 
and Dominant optic atrophy (DOA) are examples of the dire consequences of gene 
mutations that affect mitochondrial dynamic (Cohn et al. 2007; Kijima et al. 2005). 
Depending on the cell type, the mitochondrial network requires more or less motility 
and adaptability, making certain subsets of cells more susceptible to mitochondrial 
dysfunction. For example, neuronal cells have high energy demands – consumes around 
20% of oxygen at rest - and critically rely on mitochondrial OXPHOS metabolism (Kann 
& Kovács 2007). Mitochondria dynamically position themselves at sites of high neuronal 
activity where mitochondrial calcium buffering and ATP production contributes to 
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support neuronal activity and some form of synaptic plasticity (Kann et al. 2003; Tang & 
Zucker 1997); the reliance of neuronal cells on mitochondrial motility to sustain complex 
signalling patterns might provide one explanation for the vulnerability of certain 
neuronal network to mitochondrial dysfunction.   
1.4.4 Cell signalling pathways and modulation of cellular response 
Mitochondria are strongly implicated in cell signalling events but our knowledge 
of this crucial interaction is still incomplete. What we know so far is that mitochondria 
are not just recipients of cellular signals which command mitochondrial activity to fulfill 
cellular requirements but rather, there exists a level of greater complexity which position 
mitochondria as active modulators of cellular functions. The ubiquitous organelles 
occupy part of the cytosol and with fusion and fission dynamically remodeling the 
network, mitochondria integrate cellular signal and influence their outcome. This is true 
for cell cycle events which have been shown to come to a halt under low energy 
conditions – an outcome of a stop signal coming from the mitochondrial network.  Cell 
division is initiated by external signals and requires sufficient nutrients and available 
ATP to synthesize protein and double in size. Glucose availability has been shown to be 
an intermediate “checkpoint” (Jones et al. 2005) which low level will be translated in the 
mitochondria by the activation of adenosine monophosphate (AMP)-activated protein 
kinase (AMPK) and reversibly interrupt the initiation of cell division. The active form of 
AMPK induces the phosphorylation of p53, a transcription factor that act on several 
genes which regulate cell cycle arrest, cellular senescence and apoptosis (Harris & 
Levine 2005). 
The mitochondria are also contributing to the shape and intensity of signalling 
pathways through their ability to uptake and release calcium ions (Ca2+). The calcium 
uptake capacity of mitochondria has been discovered very early on, even before the 
OXPHOS system (Rizzuto et al. 2012). It is constituted primarily of the mitochondrial 
Ca2+ uniporter (MCU) that selectively permits a rapid flow of calcium ions inside the 
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matrix and slower Na+/Ca2+ exchangers (mNCX) which returns Ca2+ to the cytosol. 
Increase in cellular Ca2+ concentration engages a wide range of cellular events and cells 
spend a considerable amount of energy maintaining low cytosol Ca2+ concentration – in 
the nanomolar range inside the cell compared to millimolar concentrations in the 
extracellular space – (reviewed in Clapham 2007). Increasing intracellular Ca2+ 
concentration is readily used by cells to trigger all sorts of events: neurotransmitter 
release, muscle contraction or cellular motility, and modulation of gene expression, cell 
growth and apoptosis. Interestingly, Ca2+ signalling is very variable; through different 
means of regulation, intracellular changes in Ca2+ concentration produces a spectrum of 
outcomes which lead sometimes to opposite changes in the same cell. For example, long-
term potentiation and long-term depression in neurons are two opposing consequences 
observed in certain neuronal circuit following a transient increase in intracellular Ca2+. It 
was shown that the difference lies merely in the timing and duration of Ca2+ influx (Yang 
et al. 1999, reviewed in Burgoyne 2007). Others have also demonstrated the effect of 
oscillation of intracellular Ca2+ changes in gene expression and on the redox state of the 
mitochondria (Hajnóczky et al. 1995; Dolmetsch et al. 1998). Mitochondria are not the 
main Ca2+-storage organelles, in fact, the endo/sarcoplasmic reticulum, the golgi 
apparatus, endosomes/lysosomes and secretory vesicles are stronger contributors to 
calcium homeostasis but in terms of fine tuning signal transduction where spatial 
distribution and temporal regulation of cytosolic Ca2+ transients has been shown to play 
a crucial role, the Ca2+ buffering capacity of mitochondria is relevant to cellular function.  
Mitochondrial Ca2+ uptake plays a role in neuronal plasticity, for example in post-tetanic 
potentiation (Yang et al. 1999; Yang et al. 2003), or in segregating Ca2+ diffusion in 
polarized cells such as the pancreatic acinar cells (Tinel 1999). 
1.4.5 Cell death through apoptosis 
Another well-known function of mitochondria is its role in apoptosis. Apoptosis is 
an internal cell death program essential in multicellular organism for proper embryonic 
development but also eliminates old or damaged cells in adults (tissue homeostasis) and 
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is initiated as part of the immune defense system to destroy compromised cells 
(reviewed in Wang and Youle 2009). The central role of mitochondria in cell death by 
apoptosis established itself in the mid 1990’s when both proapoptotic and antiapoptotic 
proteins were found to reside or localize upon activation on the mitochondria and with 
the notable discovery that cytochrome c release is a key event in the activation of 
caspases (Liu et al. 1996; Zamzami et al. 1996). Internal signals such as DNA damage or 
prolonged nutrient starvation lead to activation of proapoptotic proteins (e.g.: Bax and 
Bak) and inhibition of antiapoptotic Bcl-2 family proteins ultimately causing the 
permeabilization of the mitochondrial inner membrane, the loss of the electrochemical 
gradient and the release of cytochrome c in the cytosol.  Apoptosis is tightly regulated in 
the cell and a decrease or increase in apoptosis can lead to diseases such as cancer, 
autoimmune diseases or neurodegenerative disorders such as Alzheimer’s or 
Parkinson’s disease (Favaloro et al. 2012). Considering the important function attributed 
to the mitochondria in the execution of apoptotic signals, dysregulation of programmed 
cell death is another lurking consequence of mitochondrial dysfunction. 
1.5 Mitochondrial diseases 
Even though the intricate links between mitochondria and cellular function is well 
studied today, pathologic processes of mitochondrial disease still largely elude us. 
Syndromes associated with mitochondrial dysfunctions are very diverse. In some cases 
single organs are affected although most mitochondrial diseases are multisystemic 
syndromes. Symptoms can manifest themselves for the first time at any age and 
different severity levels are also commonly observed. Adding to this, disease 
phenotypes are overlapping: the same genetic defect can result in different phenotype 
expression and different gene mutations are seen in patients with similar clinical 
features (Wallace 1999; Turnbull & Rustin 2016). Defects in mitochondrial function 
unequivocally lead to human diseases but the spectrum of clinical manifestations is 
broad; neuromuscular problems, myopathy, cardiomyopathy, lactic acidosis, stroke, 
encephalopathy, optic neuropathy and deafness are among the most common symptoms 
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encountered (see Table 1). Over the years, mitochondrial diseases have been classified 
according to different criteria such as their genetic origin (nuclear or mitochondrial), 
biochemical impairments, or clinical syndromes (see Table 2).  In addition, studies of 
mitochondrial dysfunction are important to human health as a number of hereditary 
disorders (such as diabetes), age-related diseases and normal ageing are associated with 
various degrees of mitochondrial impairment (see reviewed in Gorman et al. 2016; 
Swerdlow 2011; Finsterer 2004; Kauppila et al. 2016).  
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Table 1 Common clinical manifestations of mitochondrial diseases 
Peripheral nervous system 
Myopathy (ptosis, fatigue intolerance, cramps, muscle 
aching, lactic acidosis, stiffness), polyneuropathy (weakness, 
reduced or absent tendon reflexes, neuropathic pain, restless 
legs, sicca syndrome, absent or excessive sweating) 
Central nervous system 
Developmental delay, mental retardation or regression, early 
or late onset dementia, fatigue, epilepsy, myoclonic, 
migraine, stroke-like episodes, dystonia, dyskinesia, atypical 
cerebral palsy, leukoencephalopathy, basal ganglia 
calcifications, psychosis, myelopathy, coma 
Endocrine system 
Short stature, polyphagia, failure to gain weight, diabetes 
mellitus and insipidus, hypoglycemia, thyroid and 
parathyroid dysfunction, amenorrhoea, hypogonadism, 
delayed puberty, gynaecomastia, osteoporosis, 
hyperlipidaemia, hypopituitarism, hypoparathyroidism, 
hyperaldosteronism, adrenocorticotropin deficiency 
Sensory nervous system 
Hypacusis, sensorineural deafness, tinnitus, peripheral 
vertigo, cataract, glaucoma, pigmentary retinopathy, optic 
atrophy, uveitis, acquired strabism 
Gastrointestinal system 
Paradontosis, impaired swallowing, gastro-oesophageal 
reflux, delayed gastric emptying, dysphagia, chronic 
vomiting, inability to produce digestive enzymes, 
hepatopathy with liver failure and hyperammonaemia, 
recurrent diarrhea, villous atrophy, pancreatitis, 
constipation, failure to thrive, anorexia, malabsorption, 
intestinal pseudo-obstruction 
Heart 
Impulse generation and conduction defects, myocardial 
thickening, left ventricular hypertrabeculation/non-
compaction, heart failure 
Kidney Renal tubular insufficiency, Fanconi syndrome, renal cysts 
Bone marrow Sideroblastic anaemia, leucopenia, thrombopenia, 
pancytopenia 
Adapted by permission from RightsLink Permissions John Wiley and Sons: European Journal of 
Neurology, (Mitochondriopathies, Finsterer J.), COPYRIGHT, 2004. 
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Table 2 Mitochondrial Disease Classification 
Classical classification (by acronym/syndrome) 
CPEO, KSS, Pearson syndrome, MELAS, MERRF, 
LHON, Leigh syndrome, NARP, etc.  
Biochemical classification 
Defects of substrate transport 
Defect of substrate utilization 
Defects of the Krebs cycle 
Defects of the oxidation-phosphorylation coupling 
Defects of the respiratory chain 
Genetic classification 
Disorders due to mutations in the mtDNA genes encoding for RC proteins, tRNAs or rRNAs 
Disorders due to mutations in the nDNA genes encoding for RC proteins 
Disorders du to mutations in nDNA genes encoding for non_RC proteins 
Disorders associated with the RC defects du to mutations in nDNA genes encoding for non-
mitochondrial proteins.  
Adapted by permission from RightsLink Permissions John Wiley and Sons: European Jounral of 
Neurology, (Mitochondriopathies, Finsterer J.), COPYRIGHT, 2004. 
 
It was first postulated that impairment in ATP production was at the origin of 
mitochondrial diseases and that the vast diversity in the clinical manifestation was 
attributed to the energy requirements of each organ and the degree to which a gene 
mutation impairs respiratory chain function and ATP production (Wallace 1992; Wallace 
1993). The particularity of mtDNA gene mutations which coexist with wild-type 
mtDNA molecule within a cell (heteroplasmy) also provided a rational to explain the 
variation in clinical presentations of mitochondrial diseases. Today, the engineering of 
several animal models and the identification of patients with a variety of symptoms did 
not yet provide a satisfactory explanation for the unpredictability of mitochondrial 
diseases manifestation. The double nature of the genetic origin of mitochondrial diseases 
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(nuclear or mitochondrial) and the biochemical/metabolic dysregulation that leads to 
organ failure suggest that there is a much greater complexity at play and that the 
correlation between mitochondrial ATP production impairment and organ energy 
requirement is a poor predictor of the clinical manifestations of mitochondrial diseases. 
Indeed, in order to better understand the role of mitochondrial dysfunction in human 
health and disease, the organelle should be seen for its complex involvement in cellular 
function and as such more than just a power house (McBride et al. 2006). 
A compelling discussion about the topic was formulated by several groups in the 
early 2000s (Brière et al. 2004; McBride et al. 2006). An interesting example is that of the 
optic nerve which was believed to be a vulnerable site due to its particularly high energy 
requirement. The optic nerve is the main organ affected in Leber hereditary optic 
neuropathy (LHON) but over the years, it was shown that the most common 
homoplasmic mutations causing LHON disease affect Complex I activity (Km for NADH 
and electron transfer activity) albeit without significant decrease in ATP production 
(Majander et al. 1991; Larsson et al. 1991). In addition, several more mutations were 
discovered which impairs the respiratory chain and ATP production without any 
deleterious effect on the optic nerve. This theory also fell short to explain late onset 
mitochondrial diseases and the implication of mitochondrial dysfunction in age-related 
degenerative diseases. In other words, new hypotheses were needed to explain the wide 
clinical spectrum of mitochondrial and mitochondrial-related diseases. More than 10 
years later, the complexing clinical manifestation of the majority of mitochondrial 
diseases is still widely discussed (McBride 2015; Turnbull & Rustin 2016; El-Khoury et 
al. 2013). Other hypotheses were brought forward and some remain hot topics today: 
superoxide toxicity, metabolic imbalance, accumulation of somatic mtDNA mutation 
with age, polymorphism of mtDNA, mitochondrial dynamics, etc.; but none of which 
have, on their own, been able to be a satisfactory explanation. The answer probably lay 
in the multifaceted functions of mitochondria, the cellular specific demands for 
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mitochondrial activity and additional stressors such as the environment and genetic 
predisposition.     
The question remains therefore as to which extent OXPHOS dysfunction 
contributes to disease phenotypes, which cell types are vulnerable to mitochondrial 
activity loss (within which threshold) and how other aspects of mitochondrial function 
can be integrated in our understanding of mitochondrial disease physiopathology. 
1.6 Enzyme histochemistry 
Investigating the state of the electron chain activity in single cells is easily done 
with the use of mitochondrial enzyme histochemistry. This accessible method allows the 
visualization of mitochondrial activity without disturbing the structural integrity of the 
tissue, permitting each cell to be individually analyzed. By the 1980’s, histochemical 
techniques had already identified focal mitochondrial Complex IV deficiency in diseases 
later found to be due to pathogenic, nuclear-encoded mitochondrial gene alleles (Müller-
Höcker et al. 1983) or in normal ageing of human hearts (Müller-Höcker 1989). Later, 
again using mitochondrial enzyme histochemical methods, it was found that clonal 
expansion of mtDNA mutations with age leads to COX deficiency in many human 
tissues, and in vertebrate animal models of ageing (reviewed in Baines et al. 2014). 
Enzyme histochemical techniques have an advantage in the visualization of single cell 
dysfunction, compared to other biochemical measurements of tissue homogenates, 
where the averaging of biochemical competence across individual cells can mask cell-
specific mitochondrial defects.  
Quantitative analysis of COX activity has been described by several groups, 
where the oxidation of 3-3’ diaminobenzidine (DAB) catalyzed by COX is monitored 
using microphotometric assays (Old & Johnson 1989; Gonzalez-Lima & Jones 1994; 
Melendez-Ferro et al. 2013). A major drawback of this approach is the difficulty to 
clearly distinguish pathologic loss of COX activity due to normal activity being tightly 
linked to the unique energy demands of each cell type, where even segments of a cell 
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display heterogeneous activity (Wong-Riley 1989). Given the mosaic pattern of COX-
deficiency typically observed in mitochondrial diseases, the distinction between a 
pathological decrease in COX activity and normal variation due to physiological 
characteristics is laborious. Alternatively, deficient COX activity can be revealed using a 
double-labelling method known as COX/SDH (cytochrome c oxidase / succinate 
dehydrogenase) histochemistry (Ross 2011). The COX/SDH method cleverly reveals cells 
with normal mitochondrial function in brown, through the oxidation of DAB, while cells 
with deficiencies in COX activity are revealed in blue. This dual color hinders the 
detection of low or intermediate deficiency levels which light blue color is obstructed by 
the predominant brown pigment, therefore, detection and quantification of COX 
deficiency remains incomplete (Murphy et al. 2012).  
Immunofluorescence technique is also used to quantify the presence of several 
subunits of the respiratory chain complexes in tissues (Rocha et al. 2015; Hevner & 
Wong-Riley 1989; Grünewald et al. 2014). This later approach, on the plus side, enables 
simultaneous evaluation of Complex I and Complex IV expression in a single cell. In 
addition, immunofluorescence labelling is semi-quantitative and provides reliable and 
sensitive detection of protein expression. The downsides of this approach are the costs of 
species specific antibodies, the detection of protein rather than a measurement of 
enzyme function and like DAB cytochemical methods, a stringent comparison of very 
specific areas is required in order to reveal moderate changes in protein expression. 
To obtain a greater sensitivity of a cell-by-cell detection of deficient COX activity, 
we developed a new enzyme histochemical assay that exploits the competing redox 
reactions between phenazine methosulfate (PMS), cytochrome c oxidase, and 
nitrotetrazolium blue chloride (NBT) - reagents well established in mitochondrial 
enzyme histochemistry. Old and Johnson in 1989 described with a microphotometric 
assay, optimal protocols for both the histochemical assay of SDH and COX activity. 
Their work was confirmed in mouse tissues, thereafter (Nakae & Stoward 2001). In 
addition, literature dating back to the 1950’s describes the use of PMS for the reduction 
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of NBT (Farber & Bueding 1956; Nachlas et al. 1960) as well as the interaction of reduced 
PMS with Complex IV (Kearney & Singer 1955; Löw et al. 1964; Worsfold et al. 1977; 
Brody & Engel 1964). Building up on these previous works, we uncovered that the dual 
affinity of PMS for either NBT or Complex IV can be exploited to reveal COX-deficient 
cells without the use of DAB and sequential reactions. Indeed, PMS is a strong electron 
carrier that transfers electrons from Complex II to NBT, but in a complete system where 
mitochondrial COX activity is optimal, PMS preferentially passes on electrons to 
molecular oxygen via electron acceptors located in the COX subunits (Löw et al. 1964; 
Brody & Engel 1964; McMillan 1967). We show here that the alternative enzyme 
histochemical method - hereafter named nitrotetrazolium blue exclusion assay (NBTx) - 
can efficiently reveal surprisingly low levels of COX deficiency in single cells. The 
strength of this new assay is through the catalysis of formazan only where COX activity 
is dysfunctional, leading to the direct visualization of respiratory-deficient cells rather 
than a reduction in the predicted COX activity. The NBTx assay offers the unique 
opportunity to measure and quantify COX deficiency directly and unambiguously. 
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AIMS OF THIS STUDY 
The development of a new enzyme histochemistry assay to visualize COX-
deficient cells is the main focus of this study. We pursued the idea that a direct 
assessment of COX dysfunction with a single color would improve the read-out and 
provide a stronger tool for the evaluation of COX deficiency in fresh-frozen tissue 
samples. 
With this body of work, we aimed to validate the biochemical interactions which 
regulate the new assay and demonstrate the strong correlation between COX deficiency 
and blue formazan deposition. In addition, we sought to define the limits and 
experimental set-up for a variety of tissue and organisms, including human tissues, to 
pave the way for a successful use of this new assay and improve reproducibility.  Lastly, 
we developed ways to quantify COX deficiencies in heart tissues and skeletal muscles 
and demonstrate how being able to quantify COX-deficiency at the cellular level can 
help in advancing our knowledge of the physiopathology of mitochondrial diseases as 
well as being a valuable tool to assess treatment efficacy in regards to tissue recovery 
and respiratory chain activity.       
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MATERIALS AND METHODS 
1.7 Ethics statement 
All animal work was approved by the Landesamt für Natur, Umwelt und 
Verbraucherschutz Nordrhein-Westfalen in accordance with German and European 
Union regulations (Permits 84-02.042015.A103; 84-02.05.50.15.004). 
 The use of human tissues in this study was under the ethical guidelines issued by 
the Newcastle and North Tyneside Local Research Ethics Committees (reference 
09/H0906/75 & REC ref. no.: 2001/188) and comply with the Declaration of Helsinki. 
1.8 Preparation of incubation media 
Phosphate-buffered saline (PBS, 0.1 M, pH 7.0) was prepared from mixing sodium 
dihydrogen orthophosphate monohydrate (0.04 M) to di-sodium hydrogen phosphate 
anhydrous (0.06 M).  
NBTx solution contained 5 mg NBT dissolved in 3.2 ml PBS to which thawed stock 
solutions of PMS (100 µl/ml, 2.0 mM in purified water) and sodium succinate (100 µl/ml, 
1.3 M in 0.1 M PBS) were added. Final concentrations were 130 mM sodium succinate, 2 
mM NBT and 0.2 mM PMS, pH 7.0.  
1.9 NBTx assay  
Tissue Preparation – Small pieces of heart tissue were quickly frozen in 2-
methylbutane, in a glass beaker cooled by immersion in liquid nitrogen. Frozen tissues 
were stored at -80 °C until ready to use. Testis and colons were frozen in Tissue-Tek® 
O.C.T. compound (supplied by A. Hartenstein GmbH, Wuerzburg, Germany) immersed 
into liquid nitrogen. Brain tissues were frozen slowly on dry ice. Heart tissues were cut 
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 at 7 µm whereas brains, skeletal muscles, testis and colons were cut at 10 µm with a 
cryostat at -20 °C (OFT 5000, Bright Instruments, Luton, UK), mounted on Superfrost 
Plus microscope slides (Menzel, Thermo Scientific, Waltham, MA, USA) and air-dried 
for 5 to 10 minutes. Slides were kept at -80 °C for maximum a few months to avoid the 
loss of enzyme activity. 
Staining Protocol – Slides were taken out of the -80 °C freezer and thawed briefly 
at room temperature on a slide holder without lid. Sections (3 sections per slide) were 
then covered with 1ml PBS for 10 minutes in an incubator set at the desired temperature 
(1 ml per slide). PBS was discarded and replaced with 1 ml NBTx solution. Incubation 
time and temperature varies according to tissue type. Generally, best results were 
obtained with heart sections at 18 °C for 30 minutes. Brain, skeletal muscles and testis 
required a higher incubation temperature (22 to 25 °C).  
Sections were washed briefly in purified water followed by dehydration in ethanol 
(2 minutes in 50 %, 75 %, 96 %, 100 % followed by an extra 5 minutes in 100 % ethanol). 
Finally, slides were immersed for 5 minutes in two changes of xylene before mounted on 
coverslips with Cytoseal™ (Thermo Scientific, Darmstadt, Germany). 
1.10 Inhibiting the respiratory chain  
Sodium azide and potassium cyanide were dissolved in water, malonate in 1 M 
sodium hydroxide and all other inhibitors in absolute ethanol at the following 
concentration: thenoyltrifluoroacetone (TTFA, 1 mM), atpenin A5 (0.1 mM) sodium 
azide (100 mM), potassium cyanide (100 mM), rotenone (1 mM), antimycin A (1 mM), 
myxothiazol (0.2 mM), oligomycin (3 mM) and malonate (6 M). Stock solutions were 
stored at -20 °C and thawed shortly before use. Inhibitors were added to PBS for the 
preincubation time as well as to the NBTx solution (rotenone, oligomycin, antimycin A 
1:500; myxothiazol, atpenin A5, TTFA 1:200; sodium azide, potassium cyanide 1:100, 
malonate 1:1000). Control conditions contained 5 µl/ml of 100 % ethanol or 1 µl/ml 1 M 
NaOH accordingly. All conditions retained a neutral pH value between 6.9 and 7.2. 
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1.11 Mouse tissues 
All mouse lines used in all experiments were maintained on the C57Bl/6NCrl 
nuclear background (Charles River Laboratories, Germany, strain code 027). Lrpprc 
conditional knockouts (MGI:5438915) and Surf1 knockout mice (MGI:2651426) were 
kindly provided by the group of Nils-Göran Larsson, Department of Mitochondrial 
Biology, Max Planck Institute for Biology of Ageing, Cologne. mtDNA mutator mice 
(MGI:3046825) were F1 animals born to true C57Bl/6NCrl females from the P generation 
to minimized mtDNA mutagenesis (Trifunovic et al. 2004). The mt-tRNAALA m.5024C>T 
mice (MGI:5902095) are maintained by female transmission of the mutated mtDNA in 
crosses to C57Bl/6NCrl males (Kauppila et al. 2016).   
1.12 Human tissues 
Human skeletal muscle (vastus lateralis) and cardiac tissue were obtained through 
the NHS Highly Specialised Services located within the Wellcome Centre for 
Mitochondrial Research at Newcastle University. All samples were obtained and used 
with informed consent. Human colon tissue was obtained from patients with colorectal 
tumors undergoing surgical resection.  Normal mucosa was taken from at least 20 cm 
from the resection margin. Informed written consent was obtained prior to surgery and 
samples were coded to maintain confidentiality. This project was approved by the Joint 
Ethics Committee of Newcastle and North Tyneside Health Authority (REC ref. no.: 
2001/188). All tissues were cut at 7 µm and consecutive sections were used to compare 
COX/SDH (40 minutes COX, 40 minutes SDH at 37 °C), NBTx (20 minutes at 37 °C) and 
COX-only (skeletal muscles and hearts - 40 minutes,  colons – 30 minutes at 37 °C). 
1.13 Fruit flies, Drosophila melanogaster 
Fly models were kindly provided by the group of Nils-Göran Larsson, 
Department of Mitochondrial Biology, Cologne, Germany. See references for 
maintenance and engineering of Lrpprc2 RNAi (Baggio et al. 2014) and DmPolγA – 
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compound heterozygous tamD263A/tamH1038A – (Bratic et al. 2015). Flies were quickly 
frozen in liquid nitrogen and subsequently glued on a cryostat mounting disk with 
fixing gel (Tissue-Tek® O.C.T. compound). Sections of the thorax muscles were cut at 10 
µm and mounted on microscope slides. NBTx assays were performed at 18°C for 10 
minutes. 
1.14 Hypoxic conditions 
Heart tissues were cut and sections placed on microscope slides as for the 
standard NBTx experiments. PBS buffer was placed with lid open inside an oxygen 
controlling chamber system (COY Laboratory Products) 30 minutes before the start of 
the experiment. Chamber parameters were set for 2.0 % oxygen and 5.0 % CO2. 
Temperature and humidity inside the chamber was measured around 24 °C and 22 % 
relative humidity. Microscope slides with 7 µm thin section of mouse heart tissue were 
placed inside the chamber. PBS buffer was added to the slides and incubated for 10 
minutes followed by the usual NBTx buffer for 10, 20 or 30 minutes. After the incubation 
time, slides were taken out of the chamber and transferred into water for 5 minutes, 
dehydrated in ethanol and xylene before mounting with cover slips.   
1.15 COX/SDH assay  
The protocol used here is according to a standard protocol utilized across diagnostic 
histopathology laboratories (Ross 2011). 
1.16 Succinate dehydrogenase activity 
SDH activity was measured by removing PMS from the NBTx staining solution. Without 
the presence of PMS as an intermediate electron carrier, the catalysis of NBT into formazan 
crystals is weak but independent of the activity of Complex IV. Alternatively, to mimic 100% 
COX deficiency in tissues, SDH activity was also assessed with 1 mM sodium azide in the NBTx 
solution. 
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1.17 DAB histochemistry 
3,3 diaminobenzidine tetrahydrochloride (DAB) is dissolved in purified water 
followed by an equal part of 0.2 M phosphate buffer, pH 7.0 for a final concentration of 5 
mM. Prior to staining, cytochrome c (100 µM) and catalase (0.2 mg/ml) are added.  
1.18 Laser microdissection and quantitative pyrosequencing  
Heart tissues are cut at 12 µm and collected onto PEN-membrane slides (Leica, 
Microsystems GmbH, Wetzlar, Hesse, Germany) and stained for 30 minutes using the 
NBTx assay. Areas stained blue or areas with no coloration were then laser micro-
dissected (LMD7000, Leica) and collected into sterile 0.5 ml centrifuge tube. The 
collected sections are lyzed with 10 µl of lysis buffer (50 mM Tris-HCl pH 8.5, 1% 
Tween-20, 20 mg/ml proteinase K) followed by a 2 hours incubation at 55°C. Proteinase 
K is denatured by a 10 minutes incubation at 95 °C. Pyrosequencing analysis of the 
m.5024C>T mutation was performed using a PyroMark Q24 pyrosequencer and the 
design software v2.0 (Qiagen GmbH, Hilden, Germany). A single PCR reaction amplifies 
a 178 bp PCR fragment spanning the m.5024 mutation site, using a biotinylated forward 
primer and a non-biotinylated reverse primer (forward primer: 5’-Biotin-
TTCCACCCTAGCTATCATAAGC, reverse primer: 
GTAGGTTTAATTCCTGCCAATCT). PCR products were combined with dH2O, 
PyroMark binding buffer (Qiagen) and 1 µl Streptavidin sepharose™ high performance 
beads (GE Healthcare, Little Chalfont, UK), and purified and denatured using a 
Pyromark Q24 vacuum workstation. Sequencing was carried out with PyroMark Gold 
Q24 Reagents according to manufacturer’s directions, using the sequencing primer 
(TGTAGGATGAAGTCTTACA). For calibration curves, mixture of synthetic biotin-
labelled oligos were mixed, which correspond to wild-type and mutant sequences. 
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1.19 Statistical analyses 
Pyro sequencing data was analyzed with GraphPad Prism 7 software. A one-way ANOVA 
with Dunn’s multiple comparisons test was used to establish statistical significance between the 
percentage of m.5024C>T mutations in clear versus light blue areas, white versus dark blue areas 
and light blue versus dark blue areas. 
1.20 Image acquisition, processing and analysis  
Images were obtained using a Nikon Eclipse Ci microscope and processed with 
Fiji (open-source software, Schindelin et al. 2012). The following steps were written in a 
single macro command: white balancing, color deconvolution and threshold (Huang 
and Wang 1995) followed by total image analysis of area, mean intensity and standard 
deviation values. In addition, processed images were stacked and the total pixel number 
for each intensity value (0-255) was analyzed with the histogram command. Full details 
of the macro can be found in the section Appendix A. The macro is written to process 
many images at once, making it easier to analyze groups of images. When prompted by 
the macro, select a folder containing the images. 
1.21 Quantitative analysis of skeletal muscle 
Skeletal muscles of mice hindlimb (gastrocnemius and soleus) were cut in serial 
sections of 10 µm for NBTx and SDH assays and 12 µm for myosin ATPase reactions. 
Images processed with the macro were loaded to ImageJ again and single fibres were 
selected and analyzed individually. Excel and GraphPad Prism 7 were used to compare 
maximal formazan catalysis (SDH assay) to the blue intensity generated with the NBTx 
reaction (mean relative OD).  Single cells were identified in 3 consecutive sections placed 
side-by-side on one slide. Values were normalized to the mean intensity of a large area 
of each slide to account for variability (see also Appendix B for raw data). 
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RESULTS 
1.22 Competing biochemical reactions 
In the course of our research on heart tissues of a variety of mouse models 
presenting intermediate or low level respiratory chain defects, we came across several 
difficulties when attempting to confidently assert the degree of COX deficient cells with 
available enzyme histochemistry methods (Figure 4.1). Standard sequential cytochrome 
c oxidase/succinate dehydrogenase (COX/SDH) protocol used in our laboratory fell short 
to identify COX deficiency in our mouse models. Besides the long incubation time 
required for a successful exposure of COX-deficient mitochondria, cells with low or 
intermediate levels of COX deficiency appear purple or greyish which makes detection 
and quantification difficult. Animal models with near threshold level of mitochondrial 
dysfunction display cells with a tint of blue that is confusingly close to colors observed 
in wild-type sections where the SDH activity was unsuccessfully blocked. An attempt to 
find the best parameters to reveal maximum deficient mitochondria without unmasking 
healthy ones easily becomes a struggle. 
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Figure 4.1 | Sequential COX/SDH staining has drawbacks in models with near 
threshold deficiency. (A) Heart sections of wild-type C57BL/6N mice stained at 
37°C for 20 minutes with DAB and 15 minutes SDH, shows insufficient blocking 
of SDH activity as shown with the mix of unsaturated and blueish browns. (B) 30 
minutes DAB and 30 minutes SDH appear to sufficiently block SDH. (C) 60 
minutes DAB and 30 minutes SDH reveals a much saturated and yellowish 
brown suggesting that the previous condition was only partly blocking formazan 
catalysis. (D) Surf1 knockout mouse, (E) mtDNA mutator mouse, (F) mt-tRNAALA 
mutant mouse. Number of animals tested for each condition equals at least 3. 
Scale bar, 50 µm.  
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It will be demonstrated here that a strong biochemical competition between COX 
and NBT for the acquisition of electrons from PMS forms the basis for the NBTx assay, a 
new enzyme histochemistry assay which identifies lower threshold of COX deficiency 
and allows the acquisition of quantifiable data.  
The NBTx assay involves only one color (blue formazan crystals from NBT) and is based 
on a strong biochemical competition between COX and NBT for the acquisition of 
electrons from PMS (see reaction scheme Figure 4.6). In COX-competent mitochondria, 
minimal or no catalysis of formazan takes place and cells remain colourless.  
 Using sodium succinate as a substrate and in absence of PMS, NBT reduction 
leads to visible formazan pigments accumulation - an indication of the succinate 
dehydrogenase activity (Figure 4.2A). This activity is independent of Complex IV and 
no effect is observed when blocking its oxidative activity with sodium azide (Figure 
4.2B). However, formazan formation was strongly blocked by atpenin A5 (Figure 4.2C), 
a potent Complex II inhibitor (Miyadera et al. 2003). 
Adding PMS has long been shown to improve the rate of formazan catalysis, but 
its use in tissue sections is known to be beneficial only with a COX inhibitor (Löw et al. 
1964). We therefore speculated that PMS is capable of transferring electrons to Complex 
IV and that this reaction is favored over its ability to reduce NBT. To confirm this, we 
incubated heart sections with PMS (0.2 mM), NBT (2 mM) and sodium succinate (130 
mM) in the absence of any COX inhibitors. We observed that catalysis of formazan is 
effectively suppressed, suggesting the inability of PMS to reduce NBT in the presence of 
a functional COX activity. NBT molecules remained in their oxidized form even after 
prolonged incubation (Figure 4.2D-F). As expected, NBT reduction is fully restored 
using sodium azide (1 mM) or potassium cyanide (1 mM), two COX inhibitors (Figure 
4.2G,H). Sodium succinate removal prevents this effect (Figure 4.2I).  
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Figure 4.2 | PMS engages both the activity of Complex II and Complex IV. (A) Succinic 
dehydrogenase activity is detected in wild-type heart tissues using sodium succinate as a 
substrate and NBT as a final electron acceptor (n = 3). (B) Blocking COX activity with 
sodium azide does not prevent NBT reduction (n = 3). (C) Inhibiting the quinone-binding 
site of Complex II with atpenin A5 fully blocks the transfer of electrons to NBT (500nM, n 
= 3).  Wild-type heart tissues treated with a solution containing 0.2 mM PMS in addition 
to sodium succinate and NBT significantly represses the catalysis of blue formazan 
crystals for (D) 10 minutes (E) 20 minutes or (F) 30 minutes incubation at 18°C (n =  5). 
(G) Complete reduction of NBT is rescued by chemically blocking COX with sodium 
azide (1mM, 10 minutes, n = 15), or (H) potassium cyanide (1mM, 10 minutes, n = 3). (I) 
Removing sodium succinate prevents formazan formation even in the presence of 
sodium azide (10 minutes, n = 3). Scale bar, 100 µm 
To confirm the specificity of Complex IV in preventing the transfer of electrons 
from PMS to NBT, we attempted to restore NBT reduction with various electron 
transport chain inhibitors: Complex I (rotenone, 2 µM), Complex III (antimycin A, 1 µM 
and myxothiazol, 1 µM) and inhibited ATP synthesis (oligomycin A, 6 µM). None of the 
tested inhibitors could restore NBT reduction (Figure 4.3). In addition, the source of 
electron transfer from Complex II to PMS was confirmed using antimycin A, atpenin A5 
and malonate (Figure 4.4).  
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Figure 4.3 | Inhibiting mitochondrial complexes other than Complex IV does not 
reestablish the reduction of NBT. Heart sections from wild-type mice were incubated 10 
minutes in NBTx solution containing the following inhibitors: (A) rotenone (2µM), (B) 
antimycin A (1 µM), (C) myxothiazol (1 µM), (D) oligomycin (6 µM). Representative 
images of 3 experiments. Scale bar, 100 µm. 
 
 
Figure 4.4 | Site of electron transfer from Complex II to PMS. (A) NBTx + sodium azide (1 
mM) (B) NBTx + sodium azide and antimycin A (1 µM) (C) NBTx + sodium azide and 
atpenin A5 (5 µM), (D) NBTx + sodium azide and malonate (6 mM). Representative 
images of 3 experiments. Scale bar, 100 µm.  
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Our results indicate that once reduced by Complex II, PMS will transfer electrons 
to COX or NBT bypassing the classical respiratory chain electron pathway. Thus, in the 
presence of PMS, NBT reduction into formazan only depends on the respective activities 
of Complex II and COX. 
As NBT reduction depends on the absence of COX activity and because oxygen 
is a substrate of COX, its concentration modulates COX catalytic activity and substrate 
affinity (Chandel et al. 1996), we hypothesized that formazan formation could be 
influenced by oxygen pressure and availability. This possibility was examined with 
heart tissues of young (12 weeks old) wild-type mice in a chamber containing 2% 
oxygen. Low-oxygen conditions led to a rapid accumulation of formazan pigments 
(Figure 4.5A). Likewise, elevated levels of formazan deposition were noted in young 
hearts incubated at high temperature, which we speculate increased the reaction rate 
and caused a more rapid depletion of dissolved oxygen in the incubation media (Figure 
4.5B). High relative humidity also led to a slow deposition of formazan crystals over 
time, suggesting again that oxygen depletion is an important factor which influences the 
outcome of the NBTx assay (Figure 4.5C). 
Our findings point to a strong interplay between PMS, Complex II and Complex 
IV that is independent of the rest of the respiratory chain, in agreement with previous 
reports (Farber & Bueding 1956; Nachlas et al. 1960; Kearney and Singer 1955, Löw et al. 
1964). In light of these observations, we suggest a model where PMS interacts 
preferentially with Complex IV, hindering its ability to deliver electrons to NBT. In this 
scenario, NBT reduction serves as an indicator of the loss of COX activity and thus 
enables fast and sensitive detection of COX-deficient cells (Figure 4.6). 
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Figure 4.5 | Stability of a negative signal is dependent on oxygen. Wild-type hearts from 
12 weeks old mice were used to test the stability of a negative signal. (A) Hypoxic 
conditions (2% oxygen) induced formazan deposition after 10 minutes at room 
temperature. (B) Slight variation in the temperature (between 18 and 25°C) did not 
significantly increase formazan deposition although high temperature (37°C) for heart 
tissues causes a gradual accumulation of formazan crystals. (C) Lastly, we observed that 
high relative humidity levels (65%) increase formazan deposition in a healthy tissue and 
can influence the maintenance of a colorless background at a given temperature. N = at 
least 3 for each condition.  
 
 
Figure 4.6 | Proposed interaction scheme. PMS is reduced within Complex II and 
subsequently re-oxidized by COX, leaving NBT in its colorless, oxidized form (marked as 
①). When the oxidative activity of Complex IV is either artificially blocked or deficient, 
PMS is efficiently passing electrons to NBT which triggers the formation of blue 
formazan crystals (marked as ②). 
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1.23 COX-deficient mitochondria in mouse models  
Based on the biochemical interactions described above, we predicted that deficient 
cells within tissues of transgenic mice with known COX deficiency would be revealed by 
the deposition of formazan crystals. In order to verify this, we analyzed four different 
transgenic mouse models previously characterized and presenting different levels of 
COX deficiency in the heart, namely: Lrpprc conditional knockout (Lrpprc/CKMM-cre) 
(Ruzzenente et al. 2011; Mourier et al. 2014), Surf1 knockout (Dell’Agnello et al. 2007; 
Agostino et al. 2003), the PolgAD257A mtDNA mutator (Trifunovic et al. 2004) and a mouse 
heteroplasmic for an mtDNA m.5024C>T mutation in the tRNAALA gene (mt-tRNAALA 
mice, Kauppila et al 2016). Lrpprc/CKMM-cre conditional knockout mice have an 
extensive loss of Complex IV in heart tissues, with enzyme activities decreased by 90% 
already at 12 weeks of age (Ruzzenente et al. 2011). Surf1 knockout mice are reported to 
suffer a loss between 30-50% of COX activity (Mourier et al. 2014, Dell'Agnello et al. 
2007) whereas mtDNA mutator mice lose around 25-30% (Ross et al. 2013). Mice 
harboring the mt-tRNAALA mutation show only sparse COX impairment (Kauppila et al. 
2016). The NBTx assay revealed that across all mouse models, qualitative levels of 
formazan crystal deposition correlated to the mitochondrial COX deficiency previously 
reported (Figure 4.7). The darkest blue pigments were seen in Lrpprc knockout heart 
sections, followed by Surf1 knockout, the mtDNA mutator mouse, with the lowest 
amount observed in mouse heart with the mt-tRNAALA mice. The ease at which COX-
deficient cells are revealed is especially evident in the Surf1 knockout model (Figure 
4.7B). The relevance for this new approach is particularly striking when compared side-
by-side with sequential COX/SDH or COX-only histochemistry. The NBTx assay reveals 
even slight changes in COX activity, with cells clearly distinguishable with a light blue 
tint, whereas the same area in the COX/SDH serial section reveals a puzzling 
presentation of colors that vary from purple-brown or even greyish-blue, which may 
lead to ambiguous interpretations and hinder proper quantification (Murphy et al. 
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2012). Likewise, images of heart tissue reacted to DAB only show COX-positive activity 
which is a disadvantage when assessing for the presence of defective oxidative activity. 
For example, in the Lrpprc knockout heart tissue (Figure 4.7A) we identified 3 areas with 
distinct intensity of formazan deposition (labelled 1 to 3) in the NBTx assay. The same 
areas in the COX/SDH shows characteristic colour variation but the light blue, seen in 
the NBTx section of area #1, is undetected in both the COX/SDH and the COX-only 
histochemistry methods. Furthermore, when COX deficiency is partial and equally 
distributed across the tissue (as seen in Surf1 knockout mice) COX-only histochemistry 
poorly performs in revealing COX-deficient mitochondria (Figure 4.7C). Overall, the 
newly developed NBTx assay successfully reveals COX-deficient mitochondria in tissue 
sections and is more sensitive than previous methods. 
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Figure 4.7 | COX-deficient cells in mouse heart tissues. Fresh frozen heart tissues from 
mice models with COX deficiencies are shown here after COX/SDH, NBTx or COX-only 
histochemistry. (A) Lrpprc knockout (n = 3), (B) mtDNA mutator (n = 3), (C) Surf1 
knockout (n = 3) (D) mt-tRNAALA  m.5024C>T (n = 5), (E) wild-type (n = 5). Scale bar, 100 
µm.  
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1.24 Quantification of COX deficiencies 
A mosaic distribution of affected cells within a given tissue is a characteristic of 
many mitochondrial diseases. Quantifying this variation would help decipher the 
correlation between cellular OXPHOS deficiencies and disease mechanism. To 
demonstrate the high sensitivity and reproducibility of the NBTx reaction, we proceeded 
to evaluate the degree of blue formazan crystals in wild-type heart tissues exposed to 
increasing amounts of sodium azide.  
For this purpose, a simple and accessible workflow was developed using images 
captured with an upright microscope and subsequently analyzed with Fiji, a free image 
processing software (see Appendix A, Fiji Macro).  
Concentrations as low as 5 µM induced a small, detectable change in relative 
optic density (ROD) measurements followed by a gradual increase which plateaus at 
about 100 µM. A linear relationship was detected in the range of 5 to 25 µM sodium 
azide (Figure 4.8A). Completely blocking mitochondrial activity with 1 mM sodium 
azide saturates the image with an average ROD of 252 ± 1.5 (not shown).  
The variation in cellular dysfunction within the tissue is lost when the average 
ROD is calculated rather than the single cell values. We reanalyzed the images from the 
sodium azide treated heart tissues and extracted total number of pixels for each intensity 
level. Figure 8c shows a distribution curve with an important distribution of values 
across the range but interestingly, each sodium azide concentration creates a unique and 
consistent curve. The distribution of mitochondria within a cell and the variation in 
mitochondrial density between regions, as well as spaces between cells in the tissue 
might explain this distribution (see close up images in Figure 4.8B). We arbitrarily 
assigned a range of blue optical densities which would represent low, intermediate and 
high levels of COX deficiency, with the goal of establishing the distribution levels in 
distinct animal models. Plotting the number of pixels versus the blue ROD values for the 
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four different animal models resulted in similar curves (Figure 4.8D). Moreover, each 
animal was plotted individually as to assess variability within each group. 
Our data shows that the new NBTx assay accurately reveals COX deficiency with 
a very high sensitivity. The absence of brown pigments in functional mitochondria led to 
a clearer and consistent distinction of blue intensities. Our image analysis enables the 
extraction of valuable information such as: COX deficiency levels – as an average ROD 
for the entire tissue or as a spectrum within the tissue (number of pixels per ROD), 
variability within one specific genetic line (e.g.: we found that mtDNA mutator mice as 
well as Surf1 knockout mice varied substantially between each animal, whereas Lrpprc 
knockout and mt-tRNAALA mice tended to be consistent (Figure 4.8D)). 
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Figure 4.8 | Quantifying COX deficiency in heart tissues. (A) Fresh frozen heart tissues, 
sectioned at 7 µm, were exposed to different concentrations of sodium azide (0, 5, 10, 15, 
25, 50, 75 and 100 µM). Average blue intensity is calculated using Fiji software and 
plotted against each sodium azide concentration. Numbers represent mean ± SD from 6 
images per animal (n = 3, 12 week old males). Representative images for each azide 
concentration are shown under the graph. (B) Images of a section of heart tissue exposed 
to 75 µM sodium azide and the NBTx solution. Arrows show unstained areas of 
connective tissues or holes in the tissue. Image inset shows the non-homogenous 
intensity of formazan deposition within the cytoplasm. (C) Selected concentrations of 
sodium azide were plotted showing total pixel number from 6 images against each ROD 
value. Dashed lines are arbitrary range for background, low, intermediate and high 
deficiency which we transposed also to tissues of animal models. (D) Heart tissues of 
Lrpprc knockout, Surf1 knockout, mtDNA mutator and mt-tRNAALA mice compared to 
aged matched wild-type tissue. Each line represents results of replicate experiments for 
different animals. 
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In skeletal muscles, where mitochondrial activity varies greatly between muscle 
fibre types, we performed single cell analysis. Consecutives slides were used to 
distinguish fibre types with myosin ATPase reactions at pH 4.3 and 10 in addition to a 
section for histochemical assay of SDH activity. The intensity of formazan deposition as 
measured in the SDH assay was used to distinguish fiber types of similar mitochondrial 
activity. Three different types of fibers in mtDNA mutator mice hindlimb 
(gastrocnemius and soleus) - fiber type I, type II (oxidative) and type II (glycolytic) - 
were identified and used to make an evaluation of each fiber’s characteristic COX 
impairment (Figure 4.9A to H). We found no significant difference in SDH activity 
between wild-type or mutant animals (Figure 4.9I, see also Appendix B for raw data).  
 
Figure 4.9 | Quantification of skeletal muscle fibre types. Consecutive sections of the 
gastrocnemius and soleus muscles of mtDNA mutator mice were reacted to (A, E) 
myosin ATPase at pH 4.3, (B, F) myosin ATPase at pH 10, (C, G) SDH assay, (D, H) 
NBTx assay. SDH and NBTx reactions were run simultaneously at 18°C for 30 minutes. 
(I) Relative optical density (OD) depicting SDH activity in the skeletal muscle. Individual 
cells from type II (oxidative, ox or glycolytic, gly) and type I fibres were selected in wild-
type and mtDNA mutator mice. Mean relative OD ± SD (n = 3). Scale bar, 100 µm. 
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Having established that baseline SDH activity was characteristic across the 
different fiber types but uniformed between cells of the same type and is not 
significantly altered in the mtDNA mutator mice compared to wild-type mice, we 
completed our analysis with measurements of single cell COX deficiency levels. Our 
results show that fiber types with greater oxidative activity (type II (oxidative) and type 
I) are more strongly affected than glycolytic fibers (Figure 4.10A). Although in oxidative 
type II fibres COX deficiency can reach high levels (seen in our samples up to 70%), 
there is no correlation between a high COX deficiency and a high SDH activity. In other 
words, this demonstrate further that formazan deposition in the NBTx assay strongly 
correlates with COX deficiency and that the scenario where a shift in the stoichiometric 
proportion between SDH and COX in favor of more SDH molecules is unlikely (Figure 
4.10B). 
 
 
Figure 4.10 |   COX deficiency measured in 3 different fibre types. (A) Fiber type II 
(oxidative, ox), type II (glycolytic, gly) and type I from the skeletal muscle of three 
mtDNA mutator mice. Each dot represents a single cell, with 15 cells per column, with 
mean and standard deviation shown. (B) Oxidative type II fibres were used to compare 
% COX deficiency to the value of SDH activity (relative OD, mean value of 3 replicates 
with standard deviation) obtained for each single cell. 
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1.25 MtDNA heteroplasmy in heart tissues 
Cellular heteroplasmy describes the presence of wild-type and mutated copies of 
mtDNA molecules at a ratio that varies between organs and individual cells. The 
increase of this ratio towards the mutated variant is critical in the development of 
mtDNA-induced mitochondrial disease or may be a risk factor in the development of 
other age-related diseases (Stewart & Chinnery 2015). Using the NBTx assay, we were 
able to easily expose various levels of COX deficiency in heart tissues of mice with a 
point mutation in the mt-tRNAALA gene. Pups were assayed at weaning for their relative 
levels of the m.5024C>T mtDNA mutation using whole tissue quantitative 
pyrosequencing. Even mice with relatively high levels of the m.5024C>T mutation had 
low numbers of detectable dysfunctional cells within the tissue (Kaupilla et al. 2016). 
Heart sections reacted with the NBTx assay revealed areas with low (clear), intermediate 
(light blue) or high (dark blue) formazan catalysis (Figure 4.11A). We proceeded to 
isolate the different areas using laser capture microdissection with subsequent 
pyrosequencing to assay the relative m.5024C>T mutation level within the laser 
captured area. As expected, we observed a significant increase in the relative levels of 
the m.5024C>T mutation in dark or light blue areas, confirming a correlation between 
high relative levels of this pathogenic mutations and the presence of deficient COX 
activity (Figure 4.11B).  
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Figure 4.11 | Link between heteroplasmy levels and COX deficiency. (A) The high 
contrast ensued from the NBTx treatment of heart sections, allows a clear distinction of 
areas with low (clear), intermediate (light blue) or high (dark blue) formazan deposition. 
Scale bar, 20 µm. (B) Each area was collected separately with a laser dissecting 
microscope and analyzed using pyrosequencing technology. Results of at least 5 laser-
capture microdissections for each color, from 4 different mice carrying heteroplasmic 
m.5024C>T mutation in the mt-tRNAALA gene. Single point values ± SD. One-way 
ANOVA: clear versus light blue or clear versus dark blue, p < 0.05. Light blue vs dark 
blue values are not statistically different. (C) Using a laser capturing microscope, COX-
competent (clear) and COX-deficient (dark blue) cells were isolated from mt-tRNAALA 
mice treated with vehicle, low (1 x 1012 vg) or a high (5 x 1012 vg) dose of mitochondrially 
targeted zinc finger nucleases. N = at least 3 per group.   
 
We proceeded to isolate the different areas using laser capture microdissection with 
subsequent pyrosequencing to assay the relative m.5024C>T mutation level within each 
region. Our results show a significant difference between the dark or light blue areas, 
compared to the clear areas (Fig. 4.11B). There was no statistically significant difference 
between the mutation loads in light versus dark blue areas, but the distribution suggests 
a greater variability in the mutation levels in the light blue areas. We demonstrate how 
the improved visibility of the NBTx reaction provides a robust and sensitive tool to 
study within-tissue heteroplasmy and the threshold to which pathologic mtDNA 
variants affect COX activity.  
 The NBTx was subsequently used to assess changes in the levels of COX 
deficiency after infusions of mitochondrially targeted zinc finger nucleases (mtZFNs). 
Engineered mtZFNs were specifically designed to target m.5024C>T mutation in the mt-
tRNAALA mouse model so as to reduce its mutation load and test this approach as a 
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potential treatment strategy (Gammage et al 2014; Gammage et al 2018). Cardio-tropic 
adeno-associated virus (AAV9.45) was used as a vehicle and administered systemically 
to deliver mtZFNs to the host animal. After 65 days of recovery following tail-vein 
injection, animals were sacrificed and heteroplasmy levels in the heart were measured 
by pyrosequencing. Animals with high dose delivery showed a drastic drop in the 
m.5024C>T mutation load whereas low dose or vehicle had no effect (see Table 3). 
Table 3: Mutation load changes after mtZFNs treatment 
Animal # Dose 
Pre-treatment  
(mutation load in %) 
Post-treatment 
(mutation load in %) 
1 5 x 1012 vg 81 45 
2 5 x 1012 vg 74 36 
3 5 x 1012 vg 68 40 
4 5 x 1012 vg 68 25 
5 1 x 1012 vg 80 75 
6 1 x 1012 vg 69 66 
7 1 x 1012 vg 73 72 
8 1 x 1012 vg 68 69 
9 vehicle 67 72 
10 vehicle 71 71 
11 vehicle 68 69 
12 vehicle 72 72 
13 vehicle 74 74 
14 vehicle 74 75 
15 vehicle 75 74 
16 vehicle 76 76 
17 mt-tRNAALA control 76 no treatment 
18 mt-tRNAALA control 75 no treatment 
19 mt-tRNAALA control 76 no treatment 
20 mt-tRNAALA control 73 no treatment 
21 mt-tRNAALA control 80 no treatment 
22 mt-tRNAALA control 78 no treatment 
23 mt-tRNAALA control 71 no treatment 
24 mt-tRNAALA control 70 no treatment 
25 mt-tRNAALA control 69 no treatment 
 
Gammage and colleagues are reporting a successful reduction in heteroplasmy levels in 
favor of the wild-type variant. The heteroplasmy shift is accompanied by a significant 
increase in mt-tRNAALA steady-state levels. In addition, analysis of heart tissue revealed 
metabolomic signatures of a rebalancing between oxidative and glycolytic metabolism. 
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These signatures included elevated phosphoenol pyruvate and pyruvate levels, lower 
lactate levels, higher glucose levels and lower glucose-6-phosphate and fructose-6-
phosphate levels. Despite the apparent successful reduction of mutant mtDNA from 
cardiac tissue and promising recovery of metabolic function, the NBTx histochemistry 
exposed the presence of persistent COX-deficient cells. We analyzed the intensity of 
formazan deposition after the NBTx reaction in mice of 3 distinct mutation loads (70 %, 
75 %, and 80 %) to match those used for the mtZFNs treatment. We have found that 
mice of each group displayed a characteristic distribution of relative OD, reflecting the 
load of COX-deficient cells in each group (Figure 9). Based on this, we were able to 
predict where on the graph an animal of a certain mutation load would be found. 
Subsequently, we plotted the results from NBTx reacted hearts of mt-tRNAALA treated 
with low (1 x 1012 viral genomes (vg) per monomer per mouse) or high (5 x 1012 vg) 
doses and compared them with control animals (untreated animals or vehicle injection). 
We found that despite a high viral dose which shifted the heteroplasmy levels in favor 
of the wild-type mtDNA copy, similar or increased levels of COX-deficiency were 
measured (Figure 4.12). More surprisingly, mtZFNs induced reduction in m.5024C>T 
mutation was equally strong in COX-competent and COX-deficient areas, as measured 
by pyrosequencing (Figure 4.11C). The persistent COX deficiency in cells despite a 
strong reduction in mutant mtDNA load is not yet elucidated. 
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Figure 4.12 | Range of COX deficiency in the mt-tRNAALA heart. (A) Quantification of 
COX-deficient cells in mt-tRNAALA with 70, 75 and 80 % (± 2) mutation load. N = 2 
controls, 5 at 70 %, 5 at 75 % and 4 at 80 %. Each line represents the mean value of 3 
replicates. (B) Comparison of COX deficiency distribution between control and mtDNA 
ZFNs treated animals at 70 %, (C) 75 % and (D) 80 % mutation load. Each line is 1 of 3 
replicate for each animal. 2 animals at low dose and 2 animals at high dose were used for 
the 70 % group and only one animal at low dose and high dose were used at the 75 % 
and the 80 %. Due to this low number of treated animals, no statistical analysis was 
performed. 
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1.26 NBTx assay in the brain 
Brain tissues show great heterogeneity in the distribution of mitochondria which varies 
according to the type of cell and the area within the neuronal cell. It is therefore 
particularly difficult to use the current enzyme histochemical methods to expose COX-
deficiency in neuronal tissue. Protocols that succeed in revealing COX-deficiency 
nevertheless come short to properly expose low or intermediate levels. We adapted the 
NBTx assay for brain tissue by evaluating the capacity to maintain colorless tissue in 
wild-type animals as well as being able to expose low levels of COX deficiency (Figure 
4.13, 4.14 and 4.15). 
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Figure 4.13 | Detection of COX-deficient cells in brain tissue: section 1. Coronal sections 
of young (12 weeks) male mouse brain corresponding to frontal area where the following 
structures are identified: 1. Cortex, 2. Corpus callosum, 3. Lateral ventricule, 4. Striatum, 
5. Anterior commissure. 10 µm think sections reacted using the NBTx protocol or SDH 
activity with partial or full inhibition of COX activity with sodium azide. 30 minutes 
incubation at 25°C. Representative images of 3 replicates. Scale bar 50 µm.   
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Figure 4.14 | Detection of COX-deficient cells in brain tissue: section 2. The following 
structures are identified: 1. Cortex, 2. Hippocampus, 3. Thalamus, 4. Hypothalamus. 10 
µm think sections reacted using the NBTx protocol or SDH activity with partial or full 
inhibition of COX activity with sodium azide. 30 minutes incubation at 25°C. 
Representative images of 3 replicates. Scale bar 50µm.   
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Figure 4.15 | Detection of COX-deficient cells in brain tissue: section 3. The following 
structures within the cerebellum are identified: 1. Granular layer, 2. Molecular layer, 3. 
Arbor vitea, 4. 4th ventricule, 5. Reticular nucleus. 10 µm think sections reacted using the 
NBTx protocol or SDH activity with partial or full inhibition of COX activity with sodium 
azide. 30 minutes incubation at 25°C. Representative images of 3 replicates. Scale bar 50 
µm.   
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The NBTx assay in brain sections of different mouse models displaying various 
levels of COX deficiency was tested and compared to COX/SDH histochemical method. 
The Surf1 knockout revealed an easily observable deposition of blue pigments across the 
tissue (Figure 4.16A,B), whereas we found serial sections of control and mutant brain 
sections after a COX/SDH reaction difficult to analyze (Figure 4.16A,B second panel). 
The color is, as seen in the heart, similar to what one would see if the DAB incubation is 
insufficient to block all of the SDH activity in normal brain controls (Figure 4.16A, 20 
minutes COX, third panel). Within these sections, it appears as though brown deposits 
within functional mitochondria are mixed with blue deficient mitochondria, rendering 
the coloration of Surf1 knockout brain sections difficult to interpret. There was no 
ambiguity with the NBTx assay; detection of COX-deficient cells against the background 
of COX-functional cells that lack any coloration provided excellent contrast.  
 
 
Figure 4.16 | NBTx assay in brain tissue of Surf1 knockout mice. (a) Brain sections of 
wild-type mice are shown reacted either with the NBTx or the COX/SDH histochemical 
method. (b) Consecutive section of brain Surf1 knockout mice (n = 3). Scale bar, 500 µm.  
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The NBTx assay also proved efficient in mouse models where COX deficiency is not 
general but specific to targeted areas. For example, we used the Dars2NEKO mutant 
expressing Cre recombinase under the calcium/calmodulin-dependent kinase II alpha 
promoter (CaMKIIα-Cre). Depletion of the DARS2 protein in this model is targeted to 
forebrain, hippocampal and striatum neurons (Arandjanski et al. 2017). Dars2 gene 
encodes for the mitochondrially expressed aspartyl-tRNA synthetase and is linked to 
severe mitochondrial dysfunction in humans (Scheper et al. 2007). The NBTx reveals 
substantial COX deficiency in 15 weeks old animals in hippocampal and cortical 
neurons (Figure 4.17), as it was previously shown with the sequential COX/SDH 
reactions (Arandjanski et al. 2017).  
 
Figure 4.17 | NBTx assay in conditional knockout mouse models.  Brain sections of wild-
type mice remain clear in the hippocampus or the cortex area. Dars2NEKO mice on the 
other hand display strong formazan deposition. NBTx reaction, 1h at 25°C. 
representative images of 2 wild-type and 2 Dars2NEKO mice. Scale bar 50 µm. 
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One caveat with performing the NBTx assay is the assumption that a certain amount 
of mitochondrial activity is present in the tissue. The intensity of blue formazan 
deposition is proportional to the amount of Complex II molecules paired to a deficient 
Complex IV. Severe mitochondrial defects though can lead not only to a detectable 
OXPHOS deficiency but also to the loss of mtDNA and eventually cell death. For this 
reason, in tissues with low baseline levels of mitochondrial activity, the presence of 
disease causing genetic defects might render the mitochondrial activity critically low, 
making detection difficult.  
To assess the limitations of the NBTx assay, we looked at the MitoPark mouse model 
where the knockout of the nucleus encoded mitochondrial transcription factor A (Tfam) 
gene in dopamine neurons leads to the reduction of mtDNA copy number with a severe 
respiratory chain dysfunction and a progressive loss of dopamine neurons in the 
midbrain (Ekstrand et al. 2007, Ekstrand & Galter 2009). Deficiency could not be 
detected with a standard NBTx assay, even after one hour incubation. We struggled 
equally to detect deficiency using the standard COX/SDH protocol. In this mouse model, 
it is reasonable to speculate that COX deficiency remains undetected because of a 
critically low level of mitochondrial activity and neuronal cell death. Indeed, deficient 
mitochondria were finally detected by changing the protocol to a long incubation of 2 
hours (with a change of solution after the first hour), which suggest that the overall 
mitochondrial activity in this model is low due to impaired mitochondrial biogenesis 
and cell death. This was consistent with the incubation time also needed for the 
COX/SDH assay to reveal COX-deficient cells (Figure 4.18). This later set of data 
highlights the importance of considering mitochondrial content and cell death when 
interpreting negative data. The successful application of a considerably longer 
incubation time is, on the other hand, a good demonstration of the versatility and 
potential of the NBTx assay. 
  
NBTx Assay, M.-L. Simard 
 
57 
 
 
Figure 18 | NBTx assay in conditional knockout mouse models. Sections of midbrain 
area from wild-type or MitoPark mice reacted 2 hours in NBTx medium. Last panel 
shows midbrain of MitoPark mice after serial COX/SDH reaction (60 minutes in DAB 
solution followed by 2 hours in SDH solution). N = 3, Scale bar, 50 µm.  
 
We proceeded with the evaluation of a few other mouse organs which are 
commonly used in our laboratories as an example of how various tissues respond to the 
NBTx assay. Deficient COX activity is easily revealed in colonic crypts (Figure 4.19, first 
panel, PolgAD257A mtDNA mutator mice) and in skeletal muscles (Figure 4.19, second 
panel, Surf1 knockout mice). Furthermore, small developing sperm cells in the testis 
were also successfully detected with the NBTx method (Figure 4.19, third panel, 
PolgAD257A mtDNA mutator mice). In the latter, a strong pink discoloration is easily 
recognizable. This additional pinkish color was seen in all tissue tested and is 
interpreted as a half-reduced intermediate which is partly washed away in ethanol 
(Nachlas et al. 1956, Altman 1976).  
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Figure 4.19 | NBTx assay on various mouse tissues. Detection of COX-deficient 
mitochondria was possible with several tissues taken from either mtDNA mutator mice 
or Surf1 knockout mice. First panel: colon, second panel: skeletal muscle, third panel: 
testis. Fresh frozen sections were cut at 10 µm and incubated for 30 minutes at 25°C. N = 
3 per tissue, Scale bar, 100 µm. 
 
Lastly we attempted to apply the NBTx assay on skin tissue. As anticipated, 
wild-type skin tissue remains clear and the mitochondrial activity is detected with 
formazan deposition in tissue treated with sodium azide (Figure 4.20A). Nevertheless, 
not all areas of wild-type skin tissue remain clear. Some significant amount of formazan 
is catalyzed despite the lack of COX deficiency in the wild-type tissue (Figure 4.20B).  
The reason for this unspecific deposition of formazan is unknown. One possible 
explanation is the composition of skin tissue which might interfere with proper diffusion 
of the reactants. Such conditions are not optimal and interfere with the interpretation of 
a positive signal in genetically modified animals. 
Overall, we were able to successfully distinguish COX-functional and COX-
dysfunctional regions using the single step NBTx assay in a variety of tissue types. As 
the concentration of respiratory complexes varies between tissues, incubation conditions 
need to be adjusted accordingly. For each organ, the correct incubation time and 
temperature is established by reacting wild-type tissue and assessing the best 
parameters to maintain a colorless tissue, indicating efficient PMS to COX electron 
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transfer. Additionally, incubation in SDH solution (1mM sodium azide to block all COX 
activity) provides information as to the maximum formazan deposition in a given tissue 
and whether the chosen incubation time and temperature is sufficient to expose slight 
decreases in COX activity (see full protocol Appendix C). 
 
 
Figure 4.20 | NBTx assay in skin tissue. (A) Mouse skin tissue after NBTx assay (left 
panel) or SDH activity measured with the adition of sodium azide in the NBTx solution 
(right panel). (B) Sections of skin tissue from wild-type animal showing formazan 
deposition despite the presumed healthy mitochondria. Representative images of 3 
replicates. Scale bar 50 µm    
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1.27 The application of the NBTx assay to study Drosophila melanogaster 
The fruit fly Drosophila melanogaster is becoming more commonly used as an 
alternative animal model for mitochondrial research (Sánchez-Martínez et al. 2006). We 
therefore applied the NBTx reaction to the detection of mitochondrial COX activity in 
muscle sections from the fly thorax. Wild-type flies, as well as two different genetically 
engineered models were investigated. The fly Lrpprc2 gene is one of two homologs of the 
mouse Lrpprc gene also involved in coordinating mitochondrial gene translation. 
Manipulation of the Lrpprc2 knockout or knockdown leads to a drastic loss of 
respiratory chain complexes (Baggio et al. 2014). The DmPolγA flies are flies trans-
complementing two deleterious mitochondrial polymerase gamma mutant alleles (the 
exo- deficient PolgAD257A and the processivity impairing PolgAH1134A alleles), which present 
no pathogenic phenotype (Bratic et al. 2015). However using the NBTx assay, we were 
able to observe mild deficiency in COX activity. The high Complex IV content  in the fly 
thoracic muscles require a short incubation time of only 10 minutes at 18°C to allow 
strong formazan deposition in the Lrpprc2 RNAi fly. DmPolγA muscles had only 
minimal formazan deposition, whereas wild-type healthy muscles remained colorless 
under these conditions (Figure 4.21). 
 
Figure 4.21 | Skeletal muscles from the thorax of Drosophila melanogaster stained for 10 
minutes at 18 °C. Representative images of 5 flies per genotype. Scale bar, 100 µm. 
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1.28 NBTx Assay in Human Diagnostics 
The sequential COX/SDH histochemical assay is universally-applied in 
pathology laboratories as part of the diagnostic work-up of human tissue, including 
muscle biopsies, to identify COX deficient cells (Alston et al. 2016). To test the 
applicability of the NBTx method in human diagnostics, we compared serial sections of 
NBTx images against sequential COX/SDH and COX-only reactions for a variety of 
human biopsy samples, (Figure 4.22). Seven distinct genotypes were used to evaluate 
human skeletal muscles as well as seven samples of heart tissues (Figure 4.23 and 4.24). 
We found that regardless of the genetic defect (mtDNA mutations Figure 4.22A or 
nuclear gene mutations Figure 4.22B and 4.22C) the NBTx successfully exposed the full 
range of COX-deficient cells, as predicted from the COX/SDH sections, with the 
advantage that low and intermediate levels of dysfunction were distinguished with a 
quantifiable variation in blue intensity. In contrast to the classical COX/SDH reaction, 
the NBTx assay does not identify cells with functional mitochondria, regardless of the 
COX activity level (Figure 4.22A marked I and II) but, as seen in the mouse, reveals 
dysfunctional COX activity with the accumulation of blue formazan pigments with 
varying intensity (Figure 4.22A marked III, IV and V). Thus, NBTx successfully detected 
COX-deficient cells in all three types of tissue, in patterns consistent with the COX/SDH 
method. These data show that the NBTx assay is suitable for human diagnostic work, 
revealing high-contrast sections that allow for quantification and rapid diagnosis.  
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Figure 4.22. Human tissues analyzed using COX/SDH, NBTx or COX histochemical 
methods. (A) Skeletal muscle tissue with a novel m.16015T>C MTTP mutation. Roman 
numerals point to individual cells with: I) no COX deficiency, high COX activity, II) no 
COX deficiency, low COX activity III) mild COX deficiency, low SDH activity levels, IV) 
mild COX deficiency, mild SDH activity levels, V) strong COX deficiency, high SDH 
activity levels. (B) Section of skeletal muscle from patient with identified nuclear gene 
p.(Arg371Trp) TWNK (formerly PEO1) mutation. (C) Human heart tissue, 
p.Asn238Ser;c.829_830+2her_delGAGT RMND1 mutations. (D) Sections of colonic tissue 
from patient with no known mitochondrial disease. COX-deficient colonic crypts are 
detected in elderly patients. (n = 2, 78 and 72 years old). Scale bar, 100 µm. 
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Figure 4.23 | Skeletal muscle sections from patients with various genetic background. Tissue 
was cut at 10 µm and consecutive slides were used for comparing COX/SDH to the new 
NBTx method. Scale bar, 100 µm. 
 
Figure 4.24 | Heart tissues from patients with various genetic background. Tissue was cut at 
10 µm and consecutive slides were used for comparing COX/SDH to the new NBTx method. 
Scale bar, 100 µm. 
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DISCUSSION 
Accurately quantifying COX impairment at the cellular level will contribute to 
understand the role of respiratory chain defects in mitochondrial disease processes and 
the implication of mitochondrial dysfunction in age-related diseases. The currently 
available methods for cell specific detection, like the COX-only histochemistry, 
immunolabeling of mitochondrial complex subunits or the sequential COX/SDH assay, 
involve either many steps or are limited to detection of high levels of COX deficiency, 
failing to clearly expose low or intermediate levels. Detecting deficiencies with the COX-
only histochemistry or by using immunohistochemistry methods is achieved through 
the interpretation of a reduction in signal – indicating a poor COX activity – but since 
COX activity naturally varies between cells or sections of cell bodies, mild COX 
deficiencies cannot be ascertain with the use of those methods. As a direct visualization 
of deficient COX activity, the sequential COX/SDH method improves the quantification 
of dysfunctional cells. By highlighting areas of reduced COX activity with formazan 
deposition (blue) in addition to revealing positive COX activity with DAB oxidation 
(brown), the COX/SDH method also comes short in clearly detecting mild dysfunction.  
The core of this work was to show that deficiency in cytochrome c oxidase 
activity can be detected with the simple reduction of NBT. It was demonstrated that the 
NBTx method exploits tightly competing biochemical interactions between PMS, NBT 
and Complex IV to evaluate the integrity of COX activity in an enzyme histochemical 
assay. Compare to the sequential COX/SDH reactions, the NBTx has the advantage of 
not requiring a double staining and eliminates the need for DAB. The presence of DAB 
has been reported to interfere with certain assays, such as real-time qPCR (Murphy et al. 
2012) and therefore, the capacity to reveal COX deficient cells without DAB is 
advantageous in many ways. The NBTx assay generates images with a high-contrast 
between COX-deficient and COX-competent cells and not only reduces the overall cost; 
it is quick, and allows clear identification of cells harboring even mildly COX-deficient 
mitochondria. This single-color reaction has the added advantage that simple
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 automation and quantitative analysis are possible, without having to rely on comparing 
activity levels between samples. 
The biological process driving the segregation of mutant mtDNA variants in 
some cells and not others, creating the typical mosaic distribution of COX-deficient cells 
across tissues, remains an important question to which there are currently no definite 
answers. As we demonstrated in the skeletal muscles of mtDNA mutator mice, 
individual fibers show COX deficiency with a variable intensity. With the acquisition of 
quantifiable data with the NBTx assay and, subsequently our ability to quantify fiber cell 
individually, we were able to distinguish the overall greater burden of COX-deficiency 
in oxidative type II fibers compared to glycolytic fibers. This degree of precision, to the 
best of our knowledge, had not been previously achieved. In addition, the sensitivity of 
the NBTx assay to low or intermediate levels of COX-deficiency made it possible to 
quantify the loss of COX activity in heart tissues of tRNAALA mice. This is a model with a 
single pathologic mtDNA mutation; an opportunity to study in vivo the distribution 
patterns of the mtDNA variants (heteroplasmy levels between tissues) as well as the 
consequences over the animal life span on the OXPHOS system and possibly on other 
mitochondrial functions. The ease at which cellular COX dysfunction was revealed and 
the detection of the full spectrum of deficiency with the NBTx assay permitted to 
establish that the COX deficiency burden within the heart of tRNAALA mice is predictable 
within a certain range based on the animal’s mutant mtDNA heteroplasmy level (see 
Figure 4.12). This surprising predictability opens up new avenues to address the 
complexing ways by which mutant mtDNA variants behave and their effect on COX 
activity in single cells. The NBTx assay will be advantageous in studying COX 
deficiencies in age-related mitochondrial diseases and in investigations of environmental 
factors or genetic backgrounds where their contribution to the clinical manifestations 
remains difficult to establish. Additionally, as shown here, the precision with which we 
were able to quantify COX deficiencies in tRNAALA mice enabled us to confidently 
evaluate the impact of a newly developed treatment: the injection of engineered mtZFNs 
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to eliminate the mutant variants. Hopefully more such attempts to find effective 
treatments can be supported by the NBTx assay in the future.    
The one-step NBTx assay eliminates the confounding results observed with the 
sequential COX/SDH reaction of intermediate COX deficiency (Murphy et al. 2012). 
Unarguably, the strong contrast of blue COX-deficient cells over a clear background of 
fully-functional cells in the NBTx assay offers an improvement on previous methods. 
Our results on brain sections of Surf1 constitutive KO mice illustrate how intermediate 
levels of COX activity are easily identified. Beyond primary mitochondrial disease, loss 
of mitochondrial activity in the brain is a domain of investigation in normal ageing 
processes or age-related diseases such as Alzheimer’s or Parkinson’s disease (Navarro & 
Boveris 2006; Boveris & Navarro 2008; Swerdlow 2011). Reduction of COX activity in 
aged brain tissue has been reported in humans, rodents or monkeys using COX 
cytochemical or immunohistochemical methods (Itoh et al. 1996; Bertoni-Freddari et al. 
2004; Navarro et al. 2002). Analysis of DAB accumulation or detection of immunolabeled 
Complex IV subunits is challenging because it requires imaging at very precise brain 
area and comparing those areas between samples. This limits the field of view to 
precisely where investigators make their measurements and given the heterogeneous 
distribution of mitochondrial activity in the brain, assessment of a loss of enzyme 
activity in the nervous system is difficult. Detection of COX-deficient cells in genetic 
models with neuron targeted gene knockouts, like the Dars2NEKO or the Mitopark model, 
showed that the NBTx assay can be adapted to several models which display either 
strong COX deficiency (easily detectable and quantifiable) or in severe mitochondrial 
activity loss. 
Based on the successful identification of COX deficiency in human tissues of a 
wide range of genetic background, we set the basis for establishing the NBTx within the 
diagnostic workflow. Although other approaches such as the COX/SDH, COX-only 
histochemistry or immunohistochemistry are routinely used and appreciated by 
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clinicians and pathologists, the new NBTx assay stands out as a new alternative to reveal 
the wider spectrum of COX-deficiency within a tissue.   
The new NBTx assay is a strong complimentary tool to assess deficient COX 
activity for a variety of mouse or human tissues and smaller model organisms such as 
the fly, Drosophila melanogaster. In addition, we showed the potential for the acquisition 
of quantitative data, which will support research on mitochondrial disease mechanisms 
and also in the evaluation of therapeutic approaches and anticipate that the advantages 
of this method will benefit many in the field of mitochondrial research. This new assay 
not only gives an accurate readout of deficiency, it is the first enzyme histochemistry 
assay that exploits not a single enzyme activity but rather, the ratio of activity between 2 
enzymes connected within one biochemical pathway. As such, the NBTx assay is of 
benefit for the field of mitochondrial biology research but also introduces a new avenue 
for the development of new enzyme histochemistry assays. 
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Before 
  
After   
       
 
 
 
  
   
   
   
   
   
   
   
   
   
   
   
   
1 optionalManualRoiSelection=0;//if 1 manual ROI selection is offered for each image, if 0 autothresholding is applied without callback 
  
2 
   
           
3 
   
           
4 directory=getDirectory("Choose a Directory"); 
          
5 filelist=getFileList(directory); 
           
6 filelist=cleanFilelist(filelist); 
           
7 resultpath=directory+File.separator+"ImageJ"; 
         
8 origFile=""; 
 
           
9 if(!File.exists(resultpath)){ 
           
10 
 
File.makeDirectory(resultpath); 
          
11 } 
  
           
12 run("Clear Results"); 
 
           
13 run("Set Measurements...", "area mean standard min median area_fraction redirect=None decimal=3"); 
     
14 totalArea=newArray(filelist.length); 
          
15 for(i=0;i<filelist.length;i++){ 
           
16 
 
open(filelist[i]); 
           
17 
 
origImg=getImageID; 
           
18 
 
origFile=File.nameWithoutExtension; 
         
19 
 
deconvFile=resultpath+File.separator+origFile+"_"+i+".tif"; 
       
20 
 
selectImage(origImg); 
           
21 
 
//TODO: Implement white balancing 
         
22 
 
//TODO: Implement interactive component vector creation 
       
23 
 
run("Colour Deconvolution", "vectors=[User values] [r1]=107 [g1]=86 [b1]=37 [r2]=12 [g2]=17 [b2]=14 [r3]=10 [g3]=10 [b3]=10"); 
  
 81 
 
24 
 
//selectWindow("02_1345_NBTx15min_22DC_080616_001.tif-(Colour_3)"); 
      
25 
 
close("*Colour_2*"); 
           
26 
 
//selectWindow("02_1345_NBTx15min_22DC_080616_001.tif-(Colour_2)"); 
      
27 
 
close("*Colour_3*"); 
           
28 
 
//selectWindow("02_1345_NBTx15min_22DC_080616_001.tif-(Colour_1)"); 
      
29 
 
deconvImg=getImageID; 
          
30 
 
run("Invert"); 
           
31 
 
run("Invert LUT"); 
           
32 
 
run("Duplicate...", " "); 
           
33 
 
maskImg=getImageID; 
           
34 
 
setAutoThreshold("Huang"); 
          
35 
 
setOption("BlackBackground", true); 
         
36 
 
run("Convert to Mask"); 
          
37 
 
run("Create Selection"); 
          
38 
 
if(optionalManualRoiSelection){ 
          
39 
  
discardAutothreshold=getBoolean("Would you like to change the selected ROI?"); 
    
40 
  
if(discardAutothreshold){ 
         
41 
   
close; 
          
42 
   
selectImage(deconvImg); 
        
43 
   
run("Duplicate...", " "); 
         
44 
   
maskImg=getImageID; 
         
45 
   
           
46 
   
//Prompt until user selected ROI 
        
47 
   
setSelection=-1; 
         
48 
   
while(setSelection<0){ 
         
49 
   
 
waitForUser("Create user defined selection"); 
      
50 
   
 
setSelection=selectionType(); 
       
51 
   
} 
          
52 
  
} 
           
53 
 
} 
 
           
54 
 
roiManager("Add"); 
           
55 
 
selectImage(deconvImg); 
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56 
 
roiManager("Select", i); 
          
57 
 
run("Measure"); 
           
58 
 
selectImage(deconvImg); 
          
59 
 
run("Select All"); 
           
60 
 
getStatistics(area);//assumes constant image size! 
        
61 
 
totalArea[i]=area; 
           
62 
 
save(deconvFile); 
           
63 
 
roiManager("Save", resultpath+File.separator+"RoiSet.zip"); 
       
64 
 
close("*"); 
 
           
65 } 
  
           
66 saveAs("Results", resultpath+File.separator+"Values.csv"); 
        
67 roiManager("reset"); 
 
           
68 plottitle=origFile; 
 
           
69 
   
           
70 xlabel="Image number"; 
           
71 ylabel="Stain Intensity [a.u.]"; 
           
72 thrshAreaValues=newArray(nResults); 
          
73 thrshMeanValues=newArray(nResults); 
          
74 thrshStdDevValues=newArray(nResults); 
          
75 
   
           
76 for(i=0;i<nResults;i++){ 
           
77 
 
thrshAreaValues[i]=getResult("Area", i); 
         
78 
 
thrshMeanValues[i]=getResult("Mean", i); 
         
79 
 
thrshStdDevValues[i]=getResult("StdDev", i); 
         
80 } 
  
           
81 yValues=thrshMeanValues; 
           
82 
   
           
83 Plot.create(plottitle, xlabel, ylabel); 
          
84 //Plot.setLimits(0, 5, 0, 3); 
           
85 Plot.setLineWidth(5); 
 
           
86 Plot.setColor("darkGray"); 
           
87 Plot.add("line", thrshMeanValues); 
          
88 Plot.add("error bars", thrshStdDevValues); 
          
89 
   
           
90 
   
           
91 Plot.setColor("lightGray"); 
           
92 for(i=0;i<nResults;i++){ 
           
93 
 
x=i*(1/(nResults-1)); 
           
94 
 
areaPercentage=round((thrshAreaValues[i]/totalArea[i])*100); 
       
95 
 
Plot.addText(areaPercentage+"%", x, 0.12); 
         
96 
 
row=nResults-(nResults-i); 
          
97 
 
setResult("%Area",row,areaPercentage); 
         
98 } 
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99 
   
           
100 
   
           
101 Plot.show(); 
 
           
102 saveAs("png",resultpath+File.separator+"Plot.png"); 
         
103 
   
           
104 function cleanFilelist(filelist){ 
           
105 
 
origLength=filelist.length; 
          
106 
 
cleanLength=origLength; 
          
107 
 
for(i=0;i<origLength;i++){ 
          
108 
  
if(!endsWith(filelist[i],".tif")){ 
         
109 
   
cleanLength=cleanLength-1; 
        
110 
   
filelist[i]="-"; 
         
111 
  
} 
           
112 
 
} 
 
           
113 
 
if(cleanLength==origLength) { 
          
114 
  
return filelist; 
          
115 
 
} 
 
           
116 
   
           
117 
 
cleanList=newArray(cleanLength); 
          
118 
 
idx=0; 
 
           
119 
 
for(i=0;i<origLength;i++){ 
          
120 
  
if(filelist[i]!="-"){ 
          
121 
   
cleanList[idx]=filelist[i]; 
        
122 
   
idx=idx+1; 
          
123 
  
} 
           
124 
 
} 
 
           
125 
 
return cleanList; 
           
126 } 
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NBTx Protocol 
Marie-Lune Simard 
Research Group Stewart, Genome Evolution and Aging 
Created on June 2017 
 
Material 
1. Sodium succinate dibasic hexahydrate (Sigma S2378, 100 g) 
2. Phenazine methosulfate (Sigma P9625, 500 mg) 
3. Nitrotetrazolium Blue chloride (Sigma N6876, 500 mg) 
4. Sodium azide (Sigma 71289, 50 g) 
5. Sodium dihydrogen orthophosphate monohydrate (VWR 102454R) 
6. Disodium hydrogen phosphate anhydrous(VWR 444423K) 
7. 96 % Ethanol denatured with 1 % MEK(Appli-Chem A2551, 5 L) 
8. 99 % Ethanol denatured with 1 % MEK (Appli-Chem A5007, 5 L) 
9. Superfrost Plus microscope slides from Menzel (24x60 mm, 1.5, VWR 631-0853 ) 
10. Xylene (Appli-Chem A2476, 5 L) 
11. Cytoseal (Thermo Scientific 8312-4) 
12. Cooling and heating incubator 
Reagents Preparation and Storage 
Phosphate Buffer 0.1M pH 7.0 
1. Solution A: dissolve 15.6 g sodium dihydrogen orthophosphate in 500 ml 
deionized water 
2. Solution B: dissolve 28.3 g disodium hydrogen phosphate in 1 L deionized water 
3. Mix 390 ml solution A to 610 ml solution B 
4. Adjust to pH 7.0 
5. Make up to 2 L with deionized water 
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6. Aliquot into 50 ml Falcon tubes 
7. Store at -20 °C 
Phenazine methosulfate (PMS, 2.0 mM) 
PMS solutions should be prepared in deionized water. Solutions in water are stable 
and decomposition of solutions with formation of pyocyanine and other products 
can be avoided. PMS is also very sensitive to light exposure and as such should be 
stored in a dark area.  
1. Dissolve 6.12 mg PMS in 10 ml deionized water 
2. Aliquot 410 µl into 0.5 ml tubes 
3. Store at -20 °C in a light protected area 
Nitroblue tetrazolium chloride (NBT) 
NBT solution is prepared fresh. Non-enzymatic formation of formazan crystals can 
form over time in solution. To avoid this, we prepare aliquots of 5 mg of NBT powder 
in Eppendorf tubes which we dilute in PBS when needed. 3.2ml of 0.1 M PBS is 
added to 5 mg NBT (1.875 mM final concentration).  
Sodium succinate (1.3 M)  
1. Dissolve 3.5 g in 10 ml 0.1 M phosphate buffer, pH 7.0. 
2. Aliquot 410 µl into 0.5 ml microtubes.  
3. Store at -20 °C. 
Sodium azide (100 mM) 
1. Dissolve 32.5 mg sodium azide in 5 ml 0.1 M phosphate buffer, pH 7.0. 
2. Aliquot 100 µl into 0.2 ml microtubes 
3.  Store at -20 °C. 
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Establishing Staining Conditions 
Before getting started, determining proper staining conditions is essential. Ideally, 
temperature and incubation time are optimized to obtain both colorless tissues from 
wild-type animals AND a strong and rapid deposition of blue formazan crystals when 
blocking complex IV with either sodium azide or potassium cyanide. When these two 
conditions are met, unspecific staining in healthy mitochondria is avoided and sensitive 
detection of low levels of complex IV deficiency is possible. Because mitochondrial 
enzymatic activity varies between species and organs, it is important to set up staining 
conditions that are valid for the tissue which is to be evaluated. 
1. Choose incubation temperature (see Table 1 for guidelines) 
Caution: dissolved oxygen in the incubation solution is limited and quickly depleted 
when mitochondrial activity is increased at high temperatures. Lack of oxygen will 
cause the reduction of NBT in healthy tissues. 
2. Incubate healthy tissues from young animals (e.g. 12 weeks’ old mice) for 15, 30, 45 
and 60 minutes in NBTx solution (see Basic Protocol below). Note if or when tissue 
appears blue.  
3. Adjust temperature so that tissue remains clear, preferentially even after 60 minutes. 
Troubleshooting: If tissue does not remain clear, consider the following aspects: Tissue 
thickness (7 to 12 µm are recommended), relative humidity in incubation chamber 
(below 50%), slide should not be covered (remove lid), temperature. 
4. Test formazan deposition with 1 mM sodium azide (or potassium cyanide). Add 10 µl of 
sodium azide stock solution (see section: Reagents Preparation and Storage) to 1 ml 
NBTx solution. Incubate for 30 minutes at desired temperature. 
Note: If, in the presence of 1 mM sodium azide, formazan deposition after 30 minutes 
is weak, small changes in complex IV oxidative activity in affected tissues might not 
be detectable. Consider changing parameters.   
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Basic Protocol 
1. Cut frozen tissue onto Superfrost plus microscope slides. Let sections thaw briefly to 
stick to the slide then store at -20 °C or -80 °C for long term storage. Section thickness 
can be adjusted to fit the tissue at hand (see section: Establishing Staining Conditions). 
Caution: storing tissue sections will reduce mitochondrial enzymatic activity over time.   
2. Preincubate sections 10 minutes in 0.1 M PBS at the desired temperature. 
Note: see Establishing Staining Conditions section to determine temperature. 
3. Prepare fresh NBT solution by adding 3.2 ml PBS to 5 mg NBT powder. Calculate 1 ml 
NBTx solution per slide. 
Caution: reducing the volume of solution covering tissue sections might increase 
unspecific formazan catalysis.  
4. Rapidly thaw 0.4 ml 1.3 M sodium succinate and 0.4 ml 2.0 mM phenazine 
methosulphate. Mix to 3.2 ml NBT solution. 
5. Remove PBS by tipping slides on a piece of paper and add 1 ml NBTx solution to each 
slide. 
6. Incubate for 30 minutes or according to your established staining conditions.  
7. Wash in purified water for 2 to 5 minutes. 
8. Dehydrate tissue through a series of increasing concentrations of ethanol (e.g.  50 %, 70 
%, 96 %, 100 %, 100 %), allowing at least 5 minutes in the final 100 % ethanol. 
Note: A reddish color, which is attributed to a semi-reduced form of NBT, is ethanol 
soluble and should be washed away easily in the final ethanol steps. Blue formazan is 
ethanol insoluble(Itoh et al. 1996; Bertoni-Freddari et al. 2004; Navarro et al. 2002).  
9. Proceed to two changes, 5 minutes each, in 100 % xylene.  
10. Mount with Cytoseal. 
Appendix C | NBTx Protocol 
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Figures and Tables 
Table 1: Staining Guidelines 
 Section 
Thickness 
(µm) 
Temperature 
(°C) 
Time 
(minutes) 
Human    
Heart 7 to 10 37 20-30 
Skeletal muscle 7 to 10 37 30-45 
Colon 7 to 10 37 30-45 
Mus musculus 
(C57BL/6N) 
   
Heart 7 to 12 18 to 25 30 
Brain 10 to 16 25 30 
Skeletal muscle 10 to 16 18 to 25 30 
Testis 10 to 16 25 30 
Drosophila 
melanogaster 
   
Thorax muscle 7 to 10 18 to 25 10 
 
 
  
Figure 1: Schema of the NBTx’s biochemical reactions. Succinate is used to engage the 
activity of Complex II. Phenazine methosulfate (PMS) acts as an intermediate electron 
carrier between Complex II and either Complex IV or tetrazolium salts (NBT).
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